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Abstract
Directive 2010/63/EU introduced requirements for the classification of the severity of procedures to be applied
during the project authorisation process to use animals in scientific procedures and also to report actual
severity experienced by each animal used in such procedures. These requirements offer opportunities during
the design, conduct and reporting of procedures to consider the adverse effects of procedures and how these
can be reduced to minimize the welfare consequences for the animals. Better recording and reporting of
adverse effects should also help in highlighting priorities for refinement of future similar procedures and
benchmarking good practice. Reporting of actual severity should help inform the public of the relative severity
of different areas of scientific research and, over time, may show trends regarding refinement. Consistency of
assignment of severity categories across Member States is a key requirement, particularly if re-use is con-
sidered, or the safeguard clause is to be invoked. The examples of severity classification given in Annex VIII are
limited in number, and have little descriptive power to aid assignment. Additionally, the examples given often
relate to the procedure and do not attempt to assess the outcome, such as adverse effects that may occur. The
aim of this report is to deliver guidance on the assignment of severity, both prospectively and at the end of a
procedure. A number of animal models, in current use, have been used to illustrate the severity assessment
process from inception of the project, through monitoring during the course of the procedure to the final
assessment of actual severity at the end of the procedure (Appendix 1).
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Introduction
Implementation of Directive 2010/63/EU has imposed
additional requirements related to the severity of pro-
cedures carried out on animals for scientiﬁc purposes.
Procedures need to be assigned a severity classiﬁcation
prospectively and the actual severity experienced by
each animal during the course of a procedure has to
be determined and reported in the statistical informa-
tion made publicly available annually (Commission
Implementing Decision 2012/707/EU, as amended by
2014/11/EU).1,2
Good project planning is necessary to determine a
suitable prospective severity classiﬁcation and to
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develop appropriate observational monitoring and
assessment criteria and humane end-points, tailored
to the study.3,4 Suﬃciently trained and competent
staﬀ are an absolute requirement to assess animal wel-
fare during the course of the study.
There needs to be an observational strategy and a
common recording system that captures all the necessary
data in a consistent format to facilitate continued appli-
cation of reﬁnement and enable an assessment of actual
severity to be made. This paper provides the rationale of
why such assessment is necessary and who is responsible
for it. It then develops several real examples of animal
procedures of how to do so and how this then allows
evaluation of the actual severity score for each individual
animal that has gone through the procedures.
Annex VIII of the Directive has included some add-
itional guidance on prospective severity classiﬁcation to
help achieve some common interpretation of the
Directive’s intentions.
The examples give little information on how the severity
classiﬁcation was derived and give a mix of simple single
step procedures, such as short term restraint in ametabolic
cage and more complex procedures which comprise mul-
tiple steps such as organ transplantation requiring anaes-
thesia, surgery and management of organ rejection.
Although the assignment criteria (set out in Section
II of Annex VIII) indicate that each study needs to
consider a range of factors before a classiﬁcation is
made, many within the scientiﬁc community have
raised concerns that the examples provided in Annex
VIII contain insuﬃcient information to satisfactorily
explain the rationale for the severity classiﬁcation and
that no examples are provided for some important
areas of research, such as, for example, pain and arth-
ritis. Without additional explanation, there are likely to
be considerable diﬀerences in the assignation of sever-
ity, which may ultimately give misleading information
on animal use, and, perhaps of greater concern, result
in inappropriate re-use of animals. A further potential
concern related to animal models of pain is that it is
possible for the same model to be categorised across at
least two severity classiﬁcations, depending on the
reﬁnements in the procedure. In addition to the appli-
cation of early end-points, the degree of amelioration of
pain, distress and suﬀering is a major factor.
During 2012, members of the FELASA/ECLAM/
ESLAV Working Group contributed to discussions at a
meeting arranged by the European Commission on sever-
ity classiﬁcation, and using material developed by this
group, assisted in the development of some additional
guidance and a few examples of severity classiﬁcation
which were endorsed at a National Contact Point
(NCP) meeting and can be found at the EC website.5
A main purpose of this joint FELASA/ECLAM/
ESLAV report is to provide additional information
and guidance on prospective severity classiﬁcation
and assessment of severity experienced by the animals
during the course of a procedure (actual severity),
through a number of further illustrative examples
from diﬀerent ﬁelds of research drawing on existing
systems, providing examples of diﬀerent severities and
expanding on the examples provided in Annex VIII. A
number of ‘severe’ models have been deliberately
included to illustrate areas of animal use in scientiﬁc
work not included in Annex VIII and to facilitate shar-
ing and dissemination of good practice.
Models have been chosen which, at the time of prepar-
ation of this report, were in use in fundamental and applied
research, togetherwith some examples used in safety evalu-
ation. The examples include some information on how
severity can be reduced through application of reﬁnement
strategies. Additional suggestions for reﬁnement were
incorporated following review by the parent organisations.
Although the illustrative examples are representative of
current practices, the principle remains that whenever the
use of any animal model is proposed, each component of
the study should be reviewed and challengedwhere appro-
priate to ensure that all 3R opportunities are applied.
With these additional requirements in 2010/63/EU, it
is important for all involved in the use of animals,
including those responsible for project evaluation, to
develop and agree a common understanding of and
approach to ‘severity classiﬁcation’ in order to promote
a ‘level playing ﬁeld’ within the European research com-
munity. This should thus ensure a consistent reporting
of the severity experienced by the animals during the
procedures in the statistical returns on animal use.
The regulatory framework
The new Directive 2010/63/EU on the protection of
animals used for scientiﬁc purposes was approved on
22 September 2010 and took full eﬀect in Member
States on 1 January 2013.
As with Directive 86/609/EEC, the new Directive
requires that experiments are designed to cause the
least pain, suﬀering, distress or lasting harm.
All scientiﬁc procedures will be conducted under a
project authorisation approved in each Member State
(MS) by the Competent Authority (CA). All those
applying for project authorisation will need to include
an estimate of the likely severity of each procedure.
These severity estimates will be considered by the CA
during the project evaluation process undertaken,
before a decision on project authorisation is made.
Having considered the information provided in the
application, the CA will assign a severity classiﬁcation
to each procedure (Article 38).
The actual severity experienced by each animal
during each individual procedure will be reported by
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each MS (Article 54(2)) annually, in the year in which
the procedure is completed.
Furthermore, the actual severity experienced by an
animal in any previous procedures will be a key consid-
eration in determining whether or not an animal may
be re-used in further procedures (Article 16). Animals
may only be re-used provided that the severity of the
previous procedure was ‘mild’ or ‘moderate’; that the
animal’s general state of health and well-being has been
fully restored; that the further procedure is classiﬁed as
‘mild’, ‘moderate or ‘non-recovery’ and is in accord-
ance with veterinary advice, taking account the lifetime
experience of the animal. The lifetime experience of the
animal includes all aspects of health, welfare and care
and the impact of all scientiﬁc procedures. The combin-
ation of all these eﬀects may be considered as ‘cumula-
tive’ severity. In exceptional circumstances, by way of
derogation by the CA and after a veterinary examin-
ation, an animal which has previously experienced
severe pain, distress or equivalent suﬀering may be
re-used.
Article 3 deﬁnes a procedure as ‘any use, invasive or
non-invasive, of an animal for experimental or other sci-
entiﬁc purposes, with known or unknown outcome, or
educational purposes, which may cause the animal a
level of pain, suﬀering, distress or lasting harm equivalent
to, or higher than, that caused by the introduction of a
needle in accordance with good veterinary practice’.
This deﬁnes a lower ‘threshold’ for a scientiﬁc pro-
cedure below which project authorisation will not be
necessary. This deﬁnition gives an indication of the
level of pain which could be considered as a ‘threshold’,
but there is no information given on equivalent thresh-
olds for suﬀering, distress or lasting harm.
Since the adoption of the Directive, EU guidance on
severity assessment was developed and endorsed in
2012 and additional information to promote consistent
reporting was included in a discussion paper from the
NCP meeting in January 2016.6,7
Why do we need a severity classification
system?
The inclusion of a severity classiﬁcation systemwithin the
new Directive provides an opportunity to focus continu-
ously on reﬁnement from inception to completion of a
procedure, improving the quality of science and animal
welfare, and, by the inclusion of the actual severity experi-
enced by each animal during a procedure in the Statistical
Reports, providing greater transparency and promote
improved public conﬁdence in the use of animals in
research. Over time, these publications may provide
information on trends in reﬁnement.
A number of European countries, including Finland,
Germany, Ireland, The Netherlands, Poland, Sweden,
Italy, Switzerland and the UK, and Australia, Canada
and New Zealand have, for a number of years, had in
place systems to categorise the severity of animal studies.
Many of the existing systems report prospectively,
with the number of categories varying from 3 to 9.8
None of the systems, however, use the combination of
prospective, actual and cumulative suﬀering or the clas-
siﬁcations included in the new Directive. Assignment of
prospective classiﬁcation and reporting of actual severity
are necessary to enable comparison during retrospective
review of a project, where such review is required.
The severity categories are deﬁned in Annex VIII of
the Directive as follows:
The severity of a procedure shall be determined by
the degree of pain, suﬀering, distress or lasting harm
expected to be experienced by an individual animal
during the course of the procedure.
Non-recovery:
Procedures, which are performed entirely under gen-
eral anaesthesia from which the animal shall not
recover consciousness shall be classiﬁed as non-
recovery.
Mild:
Procedures on animals as a result of which the ani-
mals are likely to experience short term mild pain,
suﬀering or distress, as well as procedures with no
signiﬁcant impairment of the wellbeing or general
condition of the animals shall be classiﬁed as mild.
Moderate:
Procedures on animals as a result of which the ani-
mals are likely to experience short term moderate
pain, suﬀering or distress, or long-lasting mild
pain, suﬀering or distress as well as procedures that
are likely to cause moderate impairment of the well-
being or general condition of the animals shall be
classiﬁed as moderate.
Severe:
Procedures on animals as a result of which the ani-
mals are likely to experience severe pain, suﬀering or
distress, or long-lasting moderate pain, suﬀering or
distress as well as procedures, that are likely to cause
severe impairment of the wellbeing or general condi-
tion of the animals shall be classiﬁed as severe.
Note: There is the possibility with exceptional and
scientiﬁcally justiﬁable reasons for Member States to
adopt a provisional measure to permit the use of a
procedure involving severe, pain, suﬀering or distress
that is likely to be long-lasting and cannot be ame-
liorated. Any such provisional measures must be
considered and approved by an EU committee for
such work to continue (Article 55).
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An estimate of severity expected to be experienced by
the animal has to be given for each scientiﬁc procedure.
This requirement provides an opportunity during the
design of the study to consider the application of the
3Rs and to ensure that the severity is reduced as far as
possible within the scientiﬁc constraints of the study.9,10
This consideration of severity should therefore
beneﬁt animals by reducing suﬀering, and may also
improve robustness of scientiﬁc design by giving oppor-
tunities to consider the eﬀects of the procedures on, for
example, physiology or behaviour where, for example,
deteriorating health/welfare could aﬀect outcomes, and
ways by which such changes can be minimised to
improve the quality and consistency of data.
The classiﬁcation will furthermore help to deﬁne
clear upper limits on animal suﬀering, and thus can
assist in the implementation of humane end-points.
The 3Rs should continue to be reviewed as the pro-
ject develops both by those directly involved in the use
of animals and by the Animal Welfare Body (AWB – as
detailed in Article 27 of the Directive).
When required, a retrospective assessment (RA) of a
project gives a further opportunity to review the welfare
costs/harms to the animals, to determine whether the
objectives have been met, and to re-consider the appro-
priateness of the severity classiﬁcation, prior to any
future study.
Who determines the severity
classification?
The application for a project authorisation by the user
or the person responsible for the project requires that a
proposed severity classiﬁcation is included for each pro-
cedure (Annex VI).
The CA which conducts the project evaluation
(Article 38) shall include an ‘assessment and assignment
of the classiﬁcation of the severity of procedures’. The
CA will consider expertise in relevant scientiﬁc areas,
experimental design, laboratory animal science or wild-
life veterinary practice and animal husbandry and care,
as appropriate for the project proposal.
Prospective severity classiﬁcation is assigned to the
procedures by the CA during project evaluation, and
this shall be based on the most severe eﬀects likely to be
experienced by an individual animal after all reﬁne-
ments have been applied.
The AWB (Articles 26 & 27) is required to follow the
development and outcome of projects and to advise on
opportunities for the application of the 3Rs within
these projects.
The actual severity of procedures will be reported by
MS in the annual statistical returns. This reﬂects the
highest severity experienced by the animal as a conse-
quence of the procedure. Such information will be
provided by the user or the person responsible for the
project, informed as necessary by input from scientists,
care staﬀ, veterinarians/suitably qualiﬁed experts
involved in the project.
The National Committees for the protection of ani-
mals used in scientiﬁc procedures (Article 49) are
expected to promote and share best practices within
the European Union. An important aspect of their
role will be to promote consistency with regard to
severity assessment.
Terminology
Some clariﬁcation and standardisation in terminology
is necessary to ensure a common approach is taken
to the assessment and assignment of severity
classiﬁcation.
The Technical Expert Working Group (TEWG) con-
vened by the European Commission in 2003 to consider
various aspects of the composition of the new Directive
made several recommendations with regard to the ter-
minology that should be used. These have not been
directly transposed and the lack of further explanation
in Annex VIII has contributed to further confusion on
what aspects of the procedures (within a project) have
to be assessed for severity.
Directive 2010/63/EU – Article 3
‘procedure’ means any use, invasive or non-invasive,
of an animal for experimental or other scientiﬁc pur-
poses, with known or unknown outcome, or educa-
tional purposes, which may cause the animal a level
of pain, suﬀering, distress or lasting harm equivalent
to, or higher than, that caused by the introduction of
a needle according to good veterinary practice. This
includes any course of action intended, or liable, to
result in the birth or hatching of an animal or the
creation and maintenance of a genetically modiﬁed
animal line in any such condition, but excludes the
killing of animals solely for the use of their organs or
tissues;
‘project’ means a programme of work having a
deﬁned scientiﬁc objective and involving one or
more procedures;
The recommendation from the TEWG
Authorisation Sub-Group was to separate the deﬁn-
ition of a project from an ‘experiment’ and recom-
mended that the term ‘procedure’ should be used
rather than ‘experiment’, to include both procedures
with known outcomes (e.g. procedures concerned with
the production of antibodies) and with unknown out-
comes (e.g. a procedure conducted to test a hypothesis).
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This concept was included but the further recom-
mended division was not.
Technique: A technical act on one or more animals
for an experimental or other scientiﬁc
purpose and which may cause that
animal or those animals pain, suﬀering,
distress or lasting harm. Examples of
technical acts would be gavage, injec-
tion, laparotomy, withholding of food/
water.
Procedure: A combination of one or more tech-
nical acts carried out on an animal for
an experimental or other scientiﬁc pur-
pose and which may cause that animal
pain, suﬀering, distress or lasting harm.
Project: A coherent programme of work aimed
at meeting a deﬁned scientiﬁc objective
or objectives and involving a combin-
ation of one or more procedures.
At a NCP meeting in October 2011, the concept of a
single and multiple-step procedure was preferred to the
use of ‘technique’, as this term is not included in the
Directive.
The term ‘procedure’ should, therefore, be used to
describe the complete series of steps (techniques) that
need to be applied to complete a particular experimen-
tal or other scientiﬁc purpose. Some procedures may
include only a single step (technique) (e.g. withdrawal
of blood from ‘normal’ animal to enable in vitro stu-
dies), but the majority will include a number of steps
(techniques) (e.g. a vaccine challenge study could
involve injection of vaccine, exposure to an infectious
agent, and sampling or biopsy of tissues).
Annex VIII in the Directive provides a number of
examples of types of procedures in the diﬀerent severity
categories, and includes a mix of single step procedures
and multiple-step procedures.
To determine the severity of a procedure, consider-
ation will need to be given to the contribution to the over-
all severity made by each step (technique) (and the
consequences of each step) within a procedure. For exam-
ple, when injecting a substance, consideration needs to be
given on the impact of the injection itself, and also on any
subsequent eﬀects of the substance being injected.
Prospective severity classification
The ﬁnal classiﬁcation of a procedure will be deter-
mined by the most severe eﬀects expected to be experi-
enced by any individual animal – this then provides a
prospective estimate of the highest level of suﬀering
likely to be encountered for any single animal within
any given procedure. This information may be helpful
in determining an appropriate monitoring strategy for
the animals and deﬁning suitable humane end-points.
Actual severity reporting
In contrast to prospective classiﬁcation, the actual
(highest) severity experienced by each individual
animal during the course of a procedure will need to
be determined, using observations recorded during the
course of the procedure, with the actual severity subse-
quently reported in the annual statistical returns.
There will therefore likely be diﬀerences in severity
between prospective severity classiﬁcation for the pro-
cedure and the actual severity reported for each of the
animals used in the procedure.
‘Below threshold’ for regulation
Directive 2010/63/EU deﬁnes a ‘procedure’ as ‘an inter-
vention which may cause the animal a level of pain, suf-
fering, distress or lasting harm equivalent to, or higher
than, that caused by the introduction of a needle accord-
ing to good veterinary practice’.
Annex VIII gives some examples that fall below this
threshold. These include minimal restraint of habitu-
ated animals, application of external telemetry devices
and minor dietary manipulations, including variations
in composition and availability, provided these are not
expected to cause any adverse eﬀects.
The Annex also notes that consideration needs to be
given when a frequency or combination of ‘below
threshold’ interventions may result in a cumulative
eﬀect which leads to the classiﬁcation of the procedure
as ‘mild or higher’.
For example, scientiﬁc investigations into novel hus-
bandry practices which involve signiﬁcant changes to
cleaning frequency and disruption to social groups are
likely to cause some suﬀering and distress and therefore
would require project authorisation.
Severity assessment of procedures and
the harm–benefit analysis of projects
The harm–beneﬁt analysis that is required for project
evaluation (Article 38) will take into consideration the
likely impact of all animals used within the project, and
therefore needs to take account of all potential harms
to all animals.
In contrast, the severity classiﬁcation of each proced-
ure will give an indication of the limit of the suﬀering to
a single animal used within the procedure.
It follows therefore that the information needed for
project evaluation needs more detail on the welfare
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harms to all animals than that provided by a simple
severity classiﬁcation applied to the procedures con-
tained within the project.
For example, in a vaccination challenge study, some
animals (unvaccinated controls) may experience severe
clinical disease, requiring an assignment of ‘severe’ to
the procedure.
However, and in contrast, it would be expected that
the majority of the animals given an eﬀective vaccine are
likely to experience no more than mild adverse eﬀects.
This detailed understanding of the likely impact on
all the animals to be used in a project is necessary to
permit an informed harm–beneﬁt analysis.10
In the example above, where the project consists of
developing a novel vaccine against a disease that is
associated with high mortality, the harm–beneﬁt ana-
lysis is likely to be in favour of the project. Of course,
this would be dependent on consideration of many
other factors, such as experience and implementation
of the 3Rs in the procedures.
Planning of a procedure
The applicant should discuss the project proposal with
the veterinarian (or suitably qualiﬁed expert where
more appropriate), care staﬀ and/or AWB to consider
the procedures to be applied, the opportunities to apply
the 3Rs, for example appropriate dosing and sampling
strategies, and to agree appropriate monitoring/assess-
ment criteria, interventions to minimise suﬀering and
where applicable humane end-points.
All those involved in severity assessment should have
a sound understanding of animal behaviour and wel-
fare and of the indicators of poor welfare, pain and
suﬀering in the species being used.4
This process ensures that all personnel involved in
the studies have an opportunity to contribute to the
study design, and to ensure that all are aware of the
potential adverse eﬀects, the animal monitoring which
will be in place and the methods to be implemented to
minimise suﬀering.
Eﬀective teamwork among all those involved is
necessary to ensure consistent interpretation and mini-
misation of suﬀering compatible with the scientiﬁc
objectives.
Training in severity assessment
Although the project leader will be responsible for
returning the data on actual severity to the CA, often
the assessment of actual severity will be undertaken by
those directly involved in carrying out procedures and
observing and caring for the animals.
Ensuring that all those involved have been appropri-
ately trained and have a good knowledge of normal and
abnormal behaviour in the species/strain being used is
therefore essential.
How should severity be assessed?
Prospective severity classification of
procedures
Many factors have to be taken into consideration in
order to determine a suitable severity classiﬁcation for
a procedure.
Although assessment is largely subjective, as more
scientiﬁc information becomes available, our under-
standing of how to recognise pain, suﬀering and dis-
tress improves, and it is therefore important to remain
abreast of developments in this rapidly evolving ﬁeld of
research.
Some examples of severity classiﬁcations of procedures
are included in Annex VIII of the Directive 2010/63/EU
and in the endorsedEUSeverity Assessment Framework.
When determining an appropriate severity classiﬁca-
tion, it is necessary to consider the impact on the
animal of each step of the planned procedure:
What is being done to the animals?
What eﬀect will this have on the animals?
How much suﬀering may it cause?
What interventions can be included to reduce the impact
on the animals?
(i) What is being done to the animals?
Consider all the steps involved in the procedure:
. Changes to normal environment, husbandry and
care practices
. Conditioning/training; handling and restraint
. Administrations/injections of substances – routes,
volumes, frequency
. Sampling – what is being sampled, from where is the
sample being taken, how much and how frequently
are the samples being taken
. Surgical and other invasive interventions
. Use of anaesthesia – local, general, regional and/or
analgesia
. Duration of study
. In the case of work in the wild – method and fre-
quency of capture, accidental capture of non-target
species, temporary housing, etc.
(ii) What eﬀect will these interventions have on the
animals?
Changes to the environment, husbandry and care
practices may initially impact animal welfare and
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cause changes in behaviour (e.g. increased aggres-
sion), but habituation of the animals will reduce poten-
tial distress.11 The same is true for handling and
restraint procedures. Behavioural conditioning of
the animals, such as adaptation to handling or struc-
tured positive reinforcement training may prepare
the animals better for procedures and mitigate these
eﬀects,
Administration of substances and sampling proced-
ures may have a negative impact on welfare, in the
short or long-term dependent on the routes, volumes
and the eﬀects of the administered substances.
Surgical interventions are likely to cause some pain,
even with good peri-operative care (including the use of
analgesics).
(iii) How much suﬀering will these interventions cause?
Consideration needs to be given to all the individual
elements, and how these will interact.
The nature, intensity and duration of each interven-
tion will impact on the overall severity.
The frequency of interventions and recovery time
between interventions also need to be considered.
Duration of the study is an important factor to con-
sider and the period over which the animal may experi-
ence pain, suﬀering or distress. For example, in a safety
evaluation/toxicology study, depending on the dose, an
acute study may cause major discomfort as a conse-
quence of drug administration but this would generally
be of short duration. In contrast, an animal may be
exposed to contaminated material (e.g. scrapie/BSE)
as a juvenile with no initial adverse eﬀects and, due to
the very long incubation period, will remain in good
health until the onset of clinical disease.
In chronic toxicology studies, animals may experi-
ence minor/moderate adverse eﬀects over many months
as a combination of daily dosing and the eﬀects of the
test substance.
For work in the wild, a careful scrutiny of the project
authorisation is extremely relevant, as severity classiﬁ-
cation of only animals used and as described under
project authorisation is to be reported.7
When, in agreement with Article 10, exemptions are
given to use wild animals captured from nature, it is
then very important to check whether capture from the
wild is considered as part of the scientiﬁc procedure and
thus that the severity reporting of that action needs to
be included. When capture and transport are not part of
the project (e.g. 100 ﬁsh captured and transported to a
lab where they will be allocated to several projects over
a period of time and two ﬁsh die during capture process
due to injury in nets) the severity is not to be reported, as
neither the capture nor the transport are a speciﬁc com-
ponent of the scientiﬁc objective.
However, if ‘taking animals from the wild’ is one of the
scientiﬁc objectives (e.g. eﬀect of capture and transport on
behaviour of animals) the severity observed must be taken
into account in the reporting of the actual severity.
It goes without saying that the appropriate welfare
during capture and transport under the Directive must
be ensured: the capture may only be carried out by
competent person(s), using methods which do not
cause avoidable pain, suﬀering, distress or lasting
harm; animals must be transported under appropriate
conditions using appropriate methods of containment;
any animal found to be injured or in poor health shall
be examined by a veterinarian or other competent
person and actions shall be taken to minimise suﬀering.
Special considerations shall be given and appropriate
measures taken for the acclimatisation, quarantine,
housing, husbandry, and care of animals taken from
the wild and, as appropriate, equally provisions for
setting them free at the end of procedures.
(iv) What interventions can be included to reduce the
impact on the animals?
How can suﬀering be minimised? How are the prin-
ciples of the 3Rs embedded in the procedure/project?
. Plan to minimise disruption to accommodation, hus-
bandry and care practices.
. Develop processes for acclimatisation, implement
training programmes as appropriate.
. Consider dosing and sampling procedures to minim-
ise impact on animals. For example, mini-pump
administration may have reduced adverse welfare
impact compared with multiple daily dosing, which
may require stressful restraint and acclimatisation to
handling. However, this needs to be balanced with
the need for surgery and the relative size of the
implant which may impact on locomotion and/or
behaviour.
. Surgical interventions must be accompanied by
eﬀective peri-operative care, and appropriate pre-
emptive and post-operative analgesia.
. During the planning of procedures, consider the
development of welfare monitoring/scoring systems
and identifying likely clinical eﬀects and determining
early end-points (consistent with scientiﬁc
objectives).
Each element of a procedure should be challenged to
ensure that the 3Rs have been properly addressed.
These issues should be considered initially by the
Project Applicant, and should be informed by discus-
sions with the veterinarian and animal care staﬀ, and
the AWB before the details of the procedure are ﬁna-
lised and the severity assigned in the application.
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Prospective discussions with all relevant personnel
will ensure that the most reﬁned procedure is developed.
Discussions should continue throughout the proced-
ure to ensure that all opportunities are taken to further
develop and adopt reﬁnements as these become avail-
able, for example through new publications.
Retrospective assessment (RA) and
assessment of ‘actual’ severity
As indicated earlier, there are requirements in the
Directive for the assessment of actual severity experi-
enced by each animal and, for certain projects, a
requirement that an RA shall be performed (Article 39).
Assessment of actual severity is necessary for a
number of reasons:
. to provide information for the annual statistical
returns on animal use;
. to enable consideration of requests for re-use of
animals;
. to contribute to the RA of projects (where required).
RA, in addition to the consideration of actual sever-
ity experienced by the animals, also requires consider-
ation of whether or not the objectives of the Project
have been achieved, and whether further opportunities
for implementation of the 3Rs have been identiﬁed. All
projects using non-human primates and all those invol-
ving ‘severe’ procedures must undergo RA.
RA may be required for other projects – these are
determined by CA during project evaluation and the
applicant informed where and when RA is required.
In order to be able to determine ‘actual’ severity
there is a need to develop recording and assessment
systems, tailored to each project which will capture all
the necessary information in a format which will facili-
tate subsequent assessment and categorisation of the
actual severity.
Development of a system for the monitor-
ing and assessment of welfare
There are many publications that oﬀer guidance on the
assessment of welfare in animals undergoing scientiﬁc
procedures (see references below). The Working Group
refers readers in particular to three articles on the cre-
ation and use of follow-up and evaluation sheets,
namely articles by Morton, Buchanan-Smith and the
report by the BVAAWF/FRAME/RSPCA/UFAW
Joint Working Group on Reﬁnement.12–14 These art-
icles not only provide background on this topic, they
discuss the beneﬁts of using such sheets for the experi-
mental animals, the animal care staﬀ, and the science of
a project. Other useful references to consider are the
Guidelines for the Assessment and Management of
Pain in Rodents and Rabbits, the Rabbit Grimace
Scale – a new method for pain assessment in rabbits
and the 1994 FELASA publication giving guidelines on
pain and distress that oﬀers general guidance on clinical
signs in rodents and lagomorphs, equating to a severity
category.15–17
An ideal assessment system would include simple,
objective measurements which could be applied consist-
ently and used to detect the onset, and monitor the
development of pain, suﬀering and distress in animals
undergoing scientiﬁc procedures. Unfortunately, such a
system is not available, nor is likely ever to be so, due to
the wide variation in behaviours and behavioural
responses among diﬀerent species, strains and individ-
ual animals and the speciﬁcs of procedures.
The use of tailored assessment systems speciﬁc to the
project, using trained and experienced personnel can
contribute to signiﬁcant reﬁnements in animal models.
Thus, it is important to list possible and/or observed
behavioural or clinical responses, which moreover
should be assessed and quantiﬁed or scored wherever
possible, and may allow for identiﬁcation of humane
end-points. For example, in some infection studies
body-temperature monitoring has been successfully
used to identify early suitable end-points in advance
of clinical evidence of disease, while still allowing the
scientiﬁc objectives of the study to be met.18
The following points should be considered in the
development of a monitoring and assessment system:
. Targeted at an individual animal and not at a group
of experimental animals, although this may be chal-
lenging where large groups are involved (e.g. in some
ﬁsh studies).
. Level of severity that is experienced by each animal
needs to be reported using the categories of mild,
moderate, or severe.
. Consideration should be given to the administrative
burden in the design of the recording system
. System should, where possible, use objective meas-
ures to assess the level of pain, suﬀering or distress
experienced by the animal during the procedure.
. System should require a deﬁnition and description of
humane end-points.
. The monitoring must capture (a) any welfare-related
issues, both expected and unexpected, that occurs
during the course of the project, (b) any reﬁnement
actions that were taken during the course of a project.
. Assessment criteria should be included to facilitate
the severity classiﬁcation. Many of the published sys-
tems advocate some form of numerical scoring
system, and rank clinical signs with severity alloca-
tion. Evidently, expertise and professional judgment
will better allow for objective scoring.
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. Standardised recording is essential. Although it is
acknowledged that all scoring systems will contain
subjective criteria to some degree, the information
recorded should be speciﬁc for the model and
species used.
Development of a suitable recording
system
. Develop an animal welfare assessment sheet tailored
to the research project through discussions with
researchers, care staﬀ and veterinarian (or suitably
qualiﬁed expert where more appropriate).
. Where applicable, score the signs of discomfort on a
convenient scale from normal (score¼ 0) to the high-
est level of severity. Use objective scoring where
possible.
. Identify intervention criteria – for example state
signs which require veterinary check/intervention
. Deﬁne the limit of acceptable or permissible severity
(e.g. a maximum score of clinical signs/behaviours
for the procedures that should not be exceeded.
This score can then be used as the score for adopting
a humane end-point.)
. Include consideration of the assessment of cumula-
tive suﬀering and criteria for re-use where applicable
. An electronic format may facilitate data entry,
allowing the details to be modiﬁed at any time in
order to permit the recording of unexpected events
and any new events when they occur during the pro-
ject and also allows easy sharing of information with
all those involved (technicians, researchers, veterin-
arians, AWB, etc.).
. The assessment sheet should be simple and easy-
to-use for experienced and inexperienced or novice
observers, based on and using agreed terminology
(e.g. FELASA Glossary of clinical signs).19
The assessment sheet should be structured in
such a way that the results of diﬀerent moments
of observing the experimental animals, such as on
handling, close up, or from a distance, can be
recorded.
. The assessment sheet should be structured such that
it can be easily modiﬁed for changing situations,
type of project, and animal species.
. The assessment sheet should, when required, allow
the recording of the time when each procedure, tech-
nique was performed, or reﬁnement introduced
during the project.
. The assessment sheet should be useful for the
entire duration of a project. Records of such assess-
ments will be useful for subsequent review of the
project and tailoring improvements for future
studies.
Assessment of actual severity
An animal’s overall or cumulative suﬀering can be esti-
mated from the nature and number of adverse and unex-
pected eﬀects that appeared during the course of a
procedure. The level of severity experienced by each
animal during the course of a procedure is inﬂuenced
by several factors, each of which should be incorporated.
The non-exhaustive list below gives an indication of
the factors which can inﬂuence the amount and level of
suﬀering that an experimental animal may experience
during a scientiﬁc procedure, and which need to be
taken into account when determining cumulative suf-
fering of an experimental animal:
. the duration of the project/procedure;
. the duration of any adverse eﬀect
. the number of procedures that were carried out on
the animal;
. the frequency of performing the procedures;
. information on whether the animal used in this pro-
ject is being re-used
. an assessment of the animal’s clinical condition and
physical wellbeing at the end of the procedure, which
should include determination of those factors that
inﬂuence body weight and body condition;
. an assessment of the impact on the animal’s behav-
iour or psychological wellbeing, for example, the
incidence of abnormal, stereotypic or aggressive
behaviours.
The following factors could also be given consider-
ation in the assessment of actual severity:
. how the animal was conditioned (e.g. adaptation,
training);
. the number of (surgical) interventions;
. the routes, volumes and frequencies of compound
and drug administration;
. the physical and chemical characteristics of the
administered compound or solution, for example,
whether the repeated injections or the injections of
acidic or basic substances induced local irritation
and necrosis;
. the routes, frequency and volume removed during
blood samplings;
. the method and frequency of restraint;
. changes in social structure/separation and single
housing of social animals.
Although each element has the potential to impact
on severity, the actual severity experienced will largely
be determined by the eﬀectiveness of the actions taken
to reduce the negative impacts of the procedure – for
example, the use of analgesics will reduce post-
operative pain.
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Determination of actual severity requires a review of
the application and consequences of the applied proced-
ures and the eﬀectiveness of actions taken to minimise
suﬀering. The actual severity can only be determined
following a review of all the eﬀects on the animal
throughout the procedure – this necessitates the main-
tenance and consideration of focussed clinical records.
The actual severity to be reported for each individual
animal should be based on the highest level of severity
experienced during the course of the procedure and not
based on the severity at the end of the procedure.
Assigning severity to an animal found dead
during study
Despite the best eﬀorts to monitor animals closely, it is
possible that an animal might be found dead as a con-
sequence of either the experimental procedure or other
unrelated causes. Some guidance on assignment of
severity in such cases is given in the Commission work-
ing document on a severity assessment framework and
in the 2016 Discussion paper.6,7 These state that: ‘For
the purposes of statistical reporting, actual severity
should primarily relate to the severity of the experimental
procedures and not unrelated incidents such as disease
outbreaks or cage ﬂooding’ and that ‘the actual severity
of an animal found dead should be reported as ‘‘severe’’
unless an informed decision can be made that the animal
did not experience severe suﬀering prior to death. If it is
unlikely that the death was preceded by severe suﬀering,
the actual severity classiﬁcation should reﬂect the known
experience prior to death. Factors such as frequency of
monitoring, use of analgesia, etc. will need to be given due
consideration.’
All deaths of animals should be carefully reviewed
among those involved (e.g. scientist/care staﬀ/veterin-
ary surgeon) as soon as possible to ensure that all rele-
vant information is available to determine whether or
not the death was procedure related and to determine
an appropriate level for reporting purposes. Whatever
the cause, measures should be taken to avoid
recurrence.
When the actual severity experienced exceeds that
predicted prospectively for the procedure, there may
be a need to notify authorities and/or revise project
authorisations.
Further guidance on the assignation of actual sever-
ity where animals are found dead can be found in the
EU discussion paper of January 2016, which provides
an illustrative decision tree to assist determination in
assigning the severity of death for the purposes of stat-
istical reporting (reproduced below).7
1. Is the death unrelated or related to the procedure the
animal was undergoing?
1.1. Unrelated
Examples of unrelated deaths:
. deﬁciencies in equipment or environmental controls
such as cage ﬂooding, heating/ventilation
malfunction;
. inappropriate husbandry or care practices such as
failure to provide adequate diet (e.g. inappropriately
balanced) or diet contaminated (e.g. poor storage);
. aggression between animals in a group housing;
. unrelated disease and infections;
. Ageing animals: deaths in animals on long-term stu-
dies should be evaluated to clearly diﬀerentiate
deaths as a result of the procedure from those as a
consequence of the natural ageing process. Deaths in
such studies should not be automatically classed as
severe, and the clinical history and condition of the
animal at the time of the last observation should be
given due consideration;
. In the case of GA breeding of an established line,
when the genetic alteration is not considered to
cause any mortalities on the basis of the welfare
assessment performed on the established line, there-
fore, it is unlikely that deaths during the breeding
programme are due to the genetic alteration.
The actual severity for the animal should reﬂect the
highest level of severity experienced during the
course of the procedure by the animal (excluding
the level of severity related to the death).
1.2. Related: proceed to question 2.
2. Can an informed decision be made about the events
leading to the death? Factors such as frequency of
monitoring, use of analgesia, etc. will need to be
given due consideration.
2.1. Yes, for example:
 animal failing to fully recover consciousness in
post-operative period, but under appropriate
analgesic regime throughout;
 no clinical abnormalities recorded throughout
the procedure, nor anticipated, but found dead
a few hours after a clinical examination.
The actual reported severity should reﬂect the sever-
ity as the result of the assumed events leading to
death.
2.2. No
The actual severity should be reported as ‘severe’.
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Re-use of animals and cumulative
suffering
Re-use of animals in further procedures is permissible
under the Directive 2010/63/EU, but is dependent on a
number of factors including the actual severity of the
previous procedure, a demonstration that the animal’s
general state of health and well-being has been fully
restored and that re-use is in accordance with veterin-
ary advice, taking into account the lifetime experience
of the animal.20
Assessing the severity that an individual scientiﬁc
procedure will cause to an animal can be diﬃcult
when animals undergo several multi-step procedures
over prolonged periods, especially when the nature of
the procedures means that the animals may also be
subjected to alterations in normal housing and care
practices (e.g. periods of single housing).
However, such an assessment is necessary to allow
re-use, and this needs to take account of the animal’s
lifetime experience. This introduces a further area for
consideration as now not only does the direct pain,
suﬀering or distress caused by the various steps in the
procedure need to be taken into account, but also some
consideration is needed of any contingent suﬀering due
to the animal’s husbandry and care environment
throughout its lifetime.
Lifetime or cumulative suﬀering can be considered
as the combination of direct suﬀering (the application
of scientiﬁc procedures), any clinical conditions from
which the animal has suﬀered (which may or may not
be due to the procedure being carried out, e.g. inter-
current disease or surgical wound) and contingent suf-
fering (housing, husbandry, transport etc.); the dur-
ation of these events must be taken into account.
The key issues which need to be taken into account
when considering lifetime experience are:
. the duration of exposure to the pain suﬀering dis-
tress or lasting harm – longer duration is more likely
to cause higher severity;
. the nature and intensity of the eﬀects on the animals;
. the interval between procedures – the shorter the
interval (usually) the less opportunity the animal
has to return to normal;
. the nature of interventions and actions that will be
taken to relieve the suﬀering;
. consideration of any contingent suﬀering.
Illustrative examples of severity
classification and reporting - Appendix 1
The attachedworked examples (Appendix 1)were current
during the evolution of this report and were real examples
of how severity classiﬁcation and reporting can be
approached. They highlight the welfare and scientiﬁc
issues to be considered, suggesting improvements that
can be made through critical review of a study design,
and provide illustrative realistic severity classiﬁcations.
The examples also include illustrations of recording sys-
tems that can be used during the course of studies to
monitor and assess actual severity and contribute elem-
ents to retrospective assessment of a project.
It is acknowledged that there may be further 3R
opportunities that have evolved since these were devel-
oped, and therefore these illustrations are not intended
to be used unaltered by research workers. Each project
will be diﬀerent in particular with regard to scientiﬁc
objectives that can inﬂuence signiﬁcantly the overall
severity of a procedure. The intention however is to
explain and promote this stepwise approach to severity
assessment. If applied as intended, the desired out-
comes of improved science and welfare and consistent
assessment and reporting of actual severity should be
achieved.
The WG has chosen animal models commonly used
in the scientiﬁc community and has for each of them
addressed the previously stated four questions asked
namely: What is being done to the animals? What
eﬀect will this have on the animals? How much suﬀering
may it cause? What interventions can be included to
reduce the impact on the animals?
Models included in this report
1. Control of infection: assessment of protection of
vaccine candidates in a murine model of tuberculosis
and screening of novel drug candidates
2. Neuropathic pain: spinal nerve ligation in the rat
3. Stroke: eﬃcacy of a novel therapeutic agent on intra-
luminal thread middle cerebral artery occlusion
(MCAO) in the marmoset
4. Cardiovascular evaluation of novel therapeutics: tel-
emetered dog model
5. Atrial ﬁbrillation: evaluation of novel antiarrhyth-
mic substances in the rabbit
6. Ecotoxicology: determination of bioaccumulation
using the ﬁsh ﬂow through test
7. Regulatory toxicology: assessment of acute oral toxi-
city in the rat
8. Pharmacokinetics: determination of the pharmaco-
kinetics after a single administration of a test sub-
stance in the dog
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Re´sume´
La directive 2010/63/EU a introduit des exigences de classification de la gravite´ des proce´dures a` appliquer au
cours du processus d’autorisation de projet visant a` utiliser des animaux dans les proce´dures scientifiques et
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e´galement a` rendre compte de la gravite´ re´elle ve´cue par chaque animal utilise´ dans de telles proce´dures.
Ces exigences offrent des possibilite´s d’examiner les effets ne´fastes des proce´dures sur les animaux et la
fac¸on dont ils peuvent eˆtre re´duits avant le commencement du travail. Un meilleur syste`me d’enregistrement
et de signalement des effets inde´sirables devrait aussi aider a` mettre en e´vidence les priorite´s d’ame´lioration
de proce´dures semblables a` l’avenir et l’analyse comparative des bonnes pratiques. Le signalement de la
gravite´ devrait contribuer a` informer le public de la gravite´ relative des diffe´rents domaines de la recherche
scientifique, et pourrait au fil du temps indiquer les tendances en matie`re de raffinement. La cohe´rence de
l’affectation des cate´gories de gravite´ dans les E´tats membres est une condition essentielle, surtout si la
re´utilisation est envisage´e, ou si la clause de sauvegarde doit eˆtre invoque´e. Les exemples de classification de
la gravite´ fournis a` l’annexe VIII sont limite´s en nombre, et ont peu de pouvoir descriptif pour aider l’affect-
ation. De plus, les exemples donne´s sont souvent lie´s a` la proce´dure et ne tentent pas d’e´valuer les re´sultats,
tels que les effets inde´sirables qui peuvent se produire. L’objectif de ce rapport est de fournir des conseils sur
l’affectation de la gravite´, tant de manie`re prospective qu’a` la fin d’une proce´dure. Un certain nombre de
mode`les animaux actuellement utilise´s ont servi a` illustrer le processus d’e´valuation de la gravite´ a` partir
de la conception du projet, par le biais d’une surveillance au cours de la proce´dure jusqu’a` l’e´valuation finale
de la gravite´ re´elle a` la fin de la proce´dure (Appendix 1).
Abstract
Die Richtlinie 2010/63/EU regelt die Anforderungen fu¨r die Einstufung des Schweregrads bei der
Projektgenehmigung zur Verwendung von Tieren in wissenschaftlichen Verfahren sowie fu¨r die Meldung
des tatsa¨chlichen Schweregrads jedes des in diesen Verfahren eingesetzten Tieres. Diese Anforderungen
bieten die Mo¨glichkeit, die negativen Auswirkungen von Verfahren auf Tiere zu beru¨cksichtigen und zu pru¨fen,
wie diese vor Arbeitsbeginn reduziert werden ko¨nnen. Bessere Erfassung und Berichterstattung u¨ber nach-
teilige Wirkungen sollten auch dazu beitragen, Priorita¨ten fu¨r die Verbesserung a¨hnlicher Verfahren und das
Benchmarking bewa¨hrter Verfahren hervorzuheben. Die Berichterstattung u¨ber den tatsa¨chlichen
Schweregrad sollte dazu beitragen, die O¨ffentlichkeit u¨ber den relativen Schweregrad der verschiedenen
Bereiche der wissenschaftlichen Forschung zu informieren, und ko¨nnte im Laufe der Zeit Trends in Bezug
auf Verbesserung aufzeigen. Eine einheitliche Zuordnung der Schweregrade durch die Mitgliedstaaten ist eine
zentrale Anforderung, insbesondere wenn die Wiederverwendung in Betracht gezogen oder die Schutzklausel
angewendet werden soll. Die in Anhang VIII aufgefu¨hrten Beispiele fu¨r die Schweregradklassifizierung sind
zahlenma¨ßig begrenzt und beschreiben die Vornahme der Zuordnung unzureichend. Außerdem beziehen sich
die genannten Beispiele oft auf das Verfahren, ohne dass versucht wird, das Ergebnis zu bewerten, wie z. B.
mo¨glicherweise auftretende nachteilige Wirkungen. Ziel dieses Berichts ist es, sowohl vorausschauende als
auch verfahrensabschließende Leitlinien fu¨r die Schweregradzuweisung zu liefern. Es wurde eine Reihe von
Tiermodellen verwendet, die derzeit im Einsatz sind, um den Prozess der Schweregradbewertung vom Beginn
des Projekts u¨ber die U¨berwachung wa¨hrend des Verfahrens bis hin zur abschließenden Bewertung der
tatsa¨chlichen Schwere zum Schluss des Verfahrens darzustellen (Appendix 1).
Resumen
La directiva 2010/63/UE introdujo requisitos para la clasificacio´n de la crudeza de los procedimientos a ser
aplicados durante el proceso de autorizacio´n de proyectos para utilizar animales en procedimientos
cientı´ficos y tambie´n para informar sobre la crudeza real ejercida sobre cada animal utilizado en dichos
procedimientos. Estos requisitos ofrecen oportunidades para considerar los efectos adversos en los animales
utilizados en los procedimientos y co´mo pueden reducirse antes de comenzar con el proyecto. Unos registros
y unos informes de los efectos secundarios tambie´n deberı´an ayudar a poner de manifiesto las prioridades
para conseguir un refinamiento de otros procedimientos futuros parecidos y un referente de buenas pra´cti-
cas. La creacio´n de informes sobre la crudeza real deberı´a ayudar a informar al pu´blico sobre la relativa
crudeza de varias a´reas de la investigacio´n cientı´fica y, con el tiempo, se podrı´an conseguir cambios en el
refinamiento. La consistencia en la asignacio´n de categorı´as de crudeza en todos los Estados Miembro es un
requisito clave, particularmente si se considera una reutilizacio´n o, de lo contrario, debera´ invocarse la
cla´usula de salvaguarda. Los ejemplos de la clasificacio´n de crudeza indicados en el Anexo VIII tienen un
nu´mero limitado y tienen poco poder descriptivo para facilitar la asignacio´n. Asimismo, los ejemplos
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facilitados a menudo guardan relacio´n con el procedimiento y no tratan de evaluar los resultados, como los
posibles efectos adversos. El objetivo de este informe es ofrecer unas directrices sobre la clasificacio´n de
crudeza, tanto con anterioridad al procedimiento como posteriormente. Se ha utilizado una serie de modelos
animales, en activo actualmente, para ilustrar el proceso de evaluacio´n de crudeza desde la creacio´n del
proyecto, durante el transcurso del procedimiento y en la evaluacio´n final de la crudeza real al final del
proyecto (Appendix 1).
Appendix 1: Illustrative examples of
severity classification and reporting
Control of infection – murine models of TB
General context. In 2010, 8.8 million cases of
active pulmonary disease were identiﬁed, with around
1.2–1.5 million people dying of this disease in that
year, making it the second largest cause of infection-
related deaths worldwide, after HIV/AIDS.1 Although
there are some eﬀective drug regimens available
for treating human TB, there are presently some
hard-to-tackle challenges in the ﬁght against this infec-
tion, that include the rise in co-infection with HIV,
the emergence of multidrug-resistant strains of
Mycobacterium tuberculosis, compliance problems
with current long-term drug regimens and the need
for new vaccines to replace BCG, which eﬃcacy has
been reported to vary between 0 and 80%.1–4 This
makes the use of murine models of TB in pre-clinical
as important as ever.5,6
Experimental infection of mice with M. tuberculosis
has been used to model human TB since the early works
of Robert Koch, and these models have since then been
of pivotal importance for the understanding of host-
pathogen interaction and for testing therapeutic and
preventive approaches to this disease.5,7–10
There are marked diﬀerences in susceptibility to TB
infection between mouse strains. However, and contrary
to what happens in most humans, no mouse strain is
capable of controlling disease to a truly latent state, and
all animals eventually succumb to the infection as a result
of progressive disease, if left untreated.11 In all strains
experimental infection is quickly followed by an accentu-
ated and continuous growth of bacterial numbers in the
lungs. The more resistant strains (e.g. the C57BL/6) are
capable of mounting a speciﬁc immune response after this
primary response, being thus able to control the disease to
a chronic stage from 3–4 weeks post-infection. During
this stage bacillary numbers in the lungs remain high
but relatively stable for several months and up to more
than a year (although lung pathology ensues) and animals
are seemingly asymptomatic. Eventually, disease recru-
desces, progressing in severity until death,1,12 if not
averted by humane end-points.13 As for the more suscep-
tible strains, these either fail to inhibit bacillary growth in
the lungs after primary infection or cannot maintain it,
resulting in rapidly progressive and overtly symptomatic
disease, which culminates in early death.14,15 Aside mouse
strain, other important parameters aﬀect resistance to
infection, such as the inoculum size (in CFUs) and the
chosen route of infection.11,16,17 Depending on these vari-
ous parameters, median survival times ofM. tuberculosis-
infected mice may vary between less than 20 days to more
than 300 days.11,18
Two diﬀerent procedures are described below, one
for vaccine testing and the other for screening of novel
drug candidates.
Illustrative procedure (1) – assessment of
protection of vaccine candidates in a murine
model of TB infection
Study design. The aim is to ﬁnd vaccine candidates that
can decrease a lung CFU count to at least 1.5 log lower
than that conferred by BCG. In a pilot study it has been
established that a standard deviation of 1.2 log puts the
eﬀect size around 1.65. For an alpha¼ 0.01 and a 90%
power, a minimum of 11 animals is required to detect
this mean diﬀerence between BCG and another antigen’s
protection. A group size of 12 animals will be used to
account for unexpected deaths. Ten groups of 12 female
BALB/c mice each will be used to test vaccine candidates
for M. tuberculosis infection. Each of the eight test com-
pound groups will be immunised by intramuscular injec-
tion (on three occasions at two week intervals) with a
vaccine candidate; one control group will be injected
with vehicle only and another control group with BCG
(‘gold-standard’ control). Thirty days after the last
immunisation, all mice will be aerosol infected with a
low dose of M. tuberculosis. Three mice from each
group will be sacriﬁced one, two and three months
post infection to assess bacillary burden in lungs and
spleen. The remaining mice will be monitored using an
adapted clinical scoring system used for infection stu-
dies,19 helping to determine humane end-points. Mice
will be group housed in solid ﬂoored cages with litter and
nesting material and cardboard tubes. Animals will be
provided food and water ad libitum. All animals will be
euthanised by anaesthetic overdose with pentobarbital
sodium.
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Consideration of specific refinements and humane end-points
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make
it worse? How will suffering be reduced to a minimum?
Adverse effects
Methodology and interven-
tions to minimise severity End-points
Intramuscular immunisa-
tion
Injection of vaccine candi-
date antigens with adju-
vant into both hind legs.
Injection can be painful
and/or cause mechan-
ical trauma and poten-
tial nerve damage.
Immune reaction may
lead to painful swelling
Previous trauma by this
antigen inoculation
technique may exacer-













other signs of non-tran-
sient distress from
injection-related inju-
ries will be euthanised.
Aerosol infection
30 days after last immun-
isation, Balb/c mice will
be placed in groups in
an exposure chamber of
an aerosol generation
device. The device is
calibrated to deliver a
specific dose of viable
bacilli into the lungs of




from handling and con-
tainment in aerosol







this stage Three to four
weeks after infection,
animals are expected to





Animals will be monitored
daily.
Relatively low inoculate
sizes (2 log10 CFU) will








tion. All animals are
expected to control
infection to a chronic
stage.




Groups of three mice from




numbers in lungs and
spleen, after one, two
and three months of the
experimental infection.
All time-points for data
collection are expected
to coincide with asymp-
tomatic or mildly symp-
tomatic stages of
disease.
Close monitoring of ani-
mals during this stage
by use of clinical score
sheets
The time-points for these
observations are
expected to occur prior
to any overt clinical
signs.
If for any reason animals
reach a predefined clin-





from each group will be




transition from a non-
clinical chronic stage to
an overtly symptomatic
stage, of progressive
Close monitoring of ani-
mals and daily weighing
of animals to determine
the turning point from
sub-clinical chronic dis-
ease to overt disease,
Humane end-point deter-
mined by clinical score.
Regardless of clinical
scoring, all animals
losing more than 15% of
body weight (compared
(continued)
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Initial prospective assessment. While bacillary
burden and immunological parameters are to be used
as indicators of vaccine protection (see interim evalu-
ation), measurement of survival provides important
data and is commonly used in this sort of study.
Objective criteria, as assessed by clinical scoring, will
however be used to implement humane end-points to
prevent animals of reaching advanced stages of disease.
Nevertheless there is the risk of at least some ani-
mals unpredictably reaching signiﬁcant levels of suﬀer-
ing and distress as a result of experimental
infection (particularly vehicle controls), as well as
from accidental nerve damage or exacerbated immune
response, hence swelling from antigen inoculation (cf. 3
i.m. injections in the thigh of mice).20,21 A prospective
severity category of MODERATE is therefore
appropriate
Could the severity category be SEVERE?
Not if the proposed reﬁnement measures are prop-
erly applied. The use of the scoring sheets in particular
may prove valuable for identifying early signs of active
disease and thus allow identifying early humane end-
points, preventing animals from signiﬁcant suﬀering.
Could the severity category be MILD?
Depending on the time point of euthanasia, animals
may not yet show signs of onset of disease therefore
classiﬁcation would be MILD.
For survival studies, in cases where the vaccine con-
trol has been eﬀective and reﬁnement opportunities
maximised, there is the possibility that those animals
may only exhibit MILD clinical signs. However, as in
mice, even BCG vaccination only reduces bacillary
burden (see introduction) and thus eventually all lose
control of the infection a severity classiﬁcation of
MILD is unlikely.
Clinical observation/scoring system. Animals were
carefully monitored from experimental infection
onward. An example of the combined clinical observa-
tion and scoring system used to help monitor the clin-
ical condition of animals throughout the procedure is
included at the end of this example.
Continued
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make
it worse? How will suffering be reduced to a minimum?
Adverse effects
Methodology and interven-
tions to minimise severity End-points
The end-point will be
assessed by clinical
score. Post-mortem
analysis will be con-
ducted to provide fur-
ther data.
severity. Signs asso-
ciated with active dis-
ease include respiratory
distress, hunched pos-
ture, lack of grooming;
inability to eat or drink,
fever and cachexia.







which will call for use of
a humane end-point.
with peak body weight)
will be euthanised.
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Apart from one animal that had to be euthanised
and removed from the study for showing a pronounced
limping gait in one hind leg after the second immunisa-
tion, all animals recovered from the immunisation
scheme with no unexpected complications. No compli-
cations were associated with aerosol infection.
All mice euthanised at the predeﬁned time-points
(three per group, three time-points) showed no overt
signs of disease.
Of the eight vaccinated groups, ﬁve of the vaccinated
groups showed lower bacillary burden in all organs
analysed, a delayed onset of disease and a signiﬁcantly
longer survival time than non-vaccinated groups, two
vaccinated groups showed levels of protection similar
to the BCG group and in the one remaining group
pathology resembled that of controls, which were the
ﬁrst to show signs of recrudescent disease. Despite dif-
ferences in time-of-onset, rate of progression and sur-
vival, all animals in the survival study eventually
showed signs of recrudescent disease and were timely
euthanised according to the predeﬁned clinical score.
No unexpected animal loss (e.g. spontaneous death)
was registered.
89 animals (euthanised at the predeﬁned time-points
except the one limping) were considered to have experi-
enced MILD severity.
31 animals (30 used in survival studies and one
euthanised because of limping were considered to
have experienced MODERATE severity
Illustrative procedure (2) – screening of
novel drug candidates in a murine model of
TB infection
Study design. The aim is to ﬁnd drugs that can match
current eﬀective antibiotics, and allow all animals to
survive up to six months without relapse, post-infec-
tion. For this period, we have observed a survival of
20% in untreated controls. To detect such a survival
Example clinical observation/scoring system











voked patterns of behav-
iour (e.g. escape reaction,
on approach)
0
Interruptions in activity, sub-
dued behaviour patterns,
even when provoked,




food and water intake
2









Dehydration Normal skin turgor 0





















without being provoked, or
when sleeping, after open-
ing of the cage and
provocation
0








tially in lateral position












A total score of 10 signals the humane end-point, at which the
animals will be euthanised.
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diﬀerence, with a 90% power and an alpha¼ 0.05, only
six animals are needed (Fisher’s exact test). However, to
accommodate unexpected losses, eight animals will be
used per group. 13 groups of n¼ 8 TB-susceptible C3H/
HeJ female mice will be used to compare the eﬃcacy of
four novel drug candidates against M. tuberculosis
infection with existing licensed products. All mice will
be infected via the intratracheal route (3 logs of CFU in
100l PBS, a dose deemed appropriate during prelim-
inary testing) by an incision in the trachea. Four weeks
post infection, four groups of mice will be administered
a low dose of their assigned test compound daily ﬁve
days a week by oral gavage, for two weeks. Four
groups will be given high doses of the test compound.
One group of control mice will be administered vehicle
only, and four other groups will be given either one of
two drugs currently used as gold-standards (GS-A, GS-
B; positive controls), in two doses for each drug.
Survival will be recorded for all groups of mice. A clin-
ical score will be used to deﬁne humane end-points.
Mice will be housed in solid ﬂoored cages with litter
and nesting material and cardboard tubes. Animals will
be provided food and water ad libitum. All surviving
animals will be euthanised by anaesthetic overdose with
pentobarbital sodium at the end of the experiment (14
days after dosing).
Consideration of specific refinements and humane
end-points.
What does this study
involve doing
to the animals?
What will the animals
experience? How much
suffering might it cause?
What might make
it worse? How will suffering be reduced to a minimum
Adverse effects
Methodology and interven-
tions to minimise severity End-points
Intratracheal instillation
Mice will be infected by




a combination of keta-
mine/medetomidine.
Adverse effects of general
anaesthesia
Post-surgical complica-
tions, pain in wound
site; reopening of
wound, infection




















candidate drugs by daily
gavage, for two weeks,
starting one week post-
infection.
Oral gavage is a difficult
procedure that may
cause fluid aspiration by
the lungs, perforation of
oesophagus or gastric
wall, irritation, swelling





induced stress or side
effects of the drug
A refinement for oral
gavage will be
attempted in a pilot-
study, by pre-coating a
gavage needle with
sucrose, a method that
has been reported to
pacify mice and induce




Any animals showing signs
of gavage-related inju-








hunched posture, lack of
All animals will be closely
monitored and assigned
a clinical score, through
the use of a clinical
Humane end-points deter-
mined by clinical score
Euthanasia when body
weight loss greater than
(continued)
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Initial prospective assessment. The use of intratra-
cheal instillation, when compared with other routes of
infection, raises additional welfare issues since it
requires general anaesthesia and, aside recovery-asso-
ciated distress, complications may arise before full
wound cicatrisation.23 However, it allows for an accur-
ate, standardised and successful inoculation. An opti-
mised surgical procedure will aim to avoid post-surgical
complications and reduce variability.
While a measure of survival is required, death will be
replaced by humane end-points based on objective and
easily measurable clinical parameters. Nevertheless, as
C3H mice cannot establish a long-lasting control of M.
tuberculosis infection, there is the possibility of at least
some animals reaching advanced stages of disease at the
time of treatment onset (particularly the vehicle con-
trols), or as a result of low experimental treatment
eﬃcacy.
A prospective severity classiﬁcation of SEVERE is
therefore appropriate.
Could the severity classiﬁcation be MODERATE?
Where disease progress is interrupted by drug treat-
ment in gold-standard controls, and possibly also in
test-compound-treated groups, these animals, may
retrospectively be found to not have exceeded the
MODERATE category.
Could the severity classiﬁcation be MILD?
No – surgical intervention under general anaesthesia
is by deﬁnition considered MODERATE.
Clinical observation/scoring system. Animals are
very carefully monitored; analgesia and local support-
ive therapy are provided as necessary.
The combined clinical observation and scoring
system used to help monitor the clinical condition of
the animals throughout the procedure is the same as
that used in the preceding example.
Example of a clinical score sheet of the animal in
Group Test Compound 3 LD found dead on Day 5
(gavage error)
Continued
What does this study
involve doing
to the animals?
What will the animals
experience? How much
suffering might it cause?
What might make
it worse? How will suffering be reduced to a minimum
Adverse effects
Methodology and interven-
tions to minimise severity End-points





analysis will be con-
ducted to provide fur-
ther data.
grooming, inability to
eat or drink, fever and
cachexia. If unrelieved





For survival studies, a pre-
defined clinical score
will be used to deter-




Any animals showing signs
of severe distress, as
determined by body
condition score, will be
euthanised.
Project number: Procedure number: . . .. . .. . .. . .. . .
Animal number: . . .. . .. . .. . .. . .. . ..
Experiment number: . . .. . .. . .. . .. . ...
Date of start of procedure: . . . /. . . /. . .
Clinical signs D1 D2 D3 D4 D5 D6 D7
Activity (0–2) 0 0 1 2
Coat condition (0–2) 0 0 1 2
Dehydration (0–2) 0 0 0 2
Discharges (0–2) 0 0 0 0
Grooming (0–2) 0 0 1 1
(continued)
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Continued
Locomotion (0–3) 0 0 0 0
Posture (0–2) 0 1 0 0
Respiration (0–2) 0 0 0 0
Vocalisations (0–1) 0 0 0 0
Other Found dead
Time of day 10.00 am 10.00 am 10.00 am 10.00 am 10.00 am
Initials of observer
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One animal died under anaesthesia. All other ani-
mals survived and recovered from intratracheal instil-
lation without any complications from this procedural
step. Gold-standard controls showed no signs of dis-
ease at the end of the treatment. The proposed pilot
study showed animals to be more compliant with oral
gavaging when sugar-coated gavage needles were used.
Nevertheless, three animals were found dead at the end
of the drug treatment (one from gold-standard con-
trols, two from Test Compound 3 LD), with post-
mortem analysis showing gavage-related injuries as
the most likely cause.
Two groups of mice treated with test compound
1(low and high dose) showed results comparable to
the vehicle controls, along with one group with low
dose of test compound 3. All of these animals reached
symptomatic stages of disease, but spontaneous death
was prevented by close monitoring for humane end-
points. Test compounds 2 and 4 prevented disease
development in both low and high- dose groups, and
test compound 3 only in high-dose treated animals.
1 animal died under anaesthesia during initial
immunisation (from negative control group): NON-
RECOVERY
71 (31 low and high-dose gold-standard drug con-
trolsþ 32 low and high dose test-drug mice and 8 high-
dose test-drug mice): although disease development
was prevented and no clinical signs developed, due to
the surgery it is MODERATE
29 animals (7 negative controlsþ 16 low and high
dose test-drug mice and 6 low-dose test drug mice):
MODERATE
3 gavage related incidents (1 animal from gold-stan-
dard group, 2 from the same low-dose treated group):
SEVERE
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Neuropathic pain – spinal nerve ligation
General context
Neuropathic pain (NP) refers to a group of pain syn-
dromes (e.g. spontaneous burning pain, allodynia,
hyperalgesia, aftersensation, paraesthesias, etc.) that
result from an initial nerve injury that causes an
increased responsiveness and pathological signal trans-
mission in the pain pathways of the nervous system.
The estimated prevalence of NP is about 1–1.5% in
the population. The largest group of patients are
those with diabetic peripheral neuropathy (representing
about 45–70% of diabetic patients) while post thera-
peutic neuralgia is the second most common cause of
NP. AIDS and cancer/chemotherapy may also predis-
pose to NP. Traumatic nerve injury may lead to a pain
syndrome termed causalgia or complex regional pain
syndrome II (CRPS II) which is considered as the
most severe NP conditions. NP is resistant to conven-
tional pain medications, and as such represents a major
therapeutic challenge. In spite of recent improvements
in therapy by the introduction of certain novel drugs,
there is still a huge unmet medical need for new medi-
cations with higher eﬃcacy, more rapid onset of action
and better side eﬀect proﬁle.
A typical and hardly tolerable NP symptom is allo-
dynia, when a mechanical or thermal stimulus (e.g. skin
contact by clothes) which does not normally provoke
pain becomes painful. Drugs with anti-allodynic eﬀects
may substantially alleviate the suﬀering of neuropathic
patients.
Experimental nerve injury in animals can be induced
by several methods which mimic diﬀerent NP aetiolo-
gies.1 Animals with streptozotocin-induced diabetes
also develop painful peripheral neuropathy, while
toxic polyneuropathy can be modelled by cytotoxic
drug treatment, e.g. vincristine or cisplatin. Various
models based on surgical injury to a major nerve
trunk (partial ligation or transection) have also been
developed which are more or less direct translations
of human CRPS II. The model under analysis uses
spinal nerve lesion to induce mechanical allodynia for
testing the eﬀects of analgesic compounds.2 A unilateral
ligation of the ﬁfth lumbar (L5) spinal nerve is per-
formed, and then animals are allowed to recover for 2
weeks. The advantage of the spinal nerve lesion model
over other nerve injury models such as the chronic con-
striction or the partial ligation of the sciatic nerve is
that the degree of injury is more uniform and therefore
the development of allodynia is more consistent.
Moreover, the motor deﬁcit and the foot deformities
after the selective L5 lesion are less severe. The
mechano-nociceptive threshold of rats are determined
by dynamic plantar aesthesiometer and/or von Frey
ﬁlaments before and after surgery.3 Thermal allodynia
can also be measured with radiant heat paw stimulator.
Test compounds are usually administered under a
repeated dose regimen starting after the recovery
period when allodynia has already developed.
Illustrative procedure
Study design. In this example, 30 male Sprague-
Dawley rats will undergo unilateral spinal nerve
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ligation. After the operation they will be allowed to
recover for 2 weeks, during which the condition of
the wound, the aﬀected limb and the general health
status including body weight measurements and obser-
vation of home cage behaviour will be monitored daily.
On the 14th postoperative day mechano-nociceptive
thresholds will be measured to conﬁrm the development
of mechanical allodynia. Only animals having a min-
imum of 20% decrease of the pre-operation threshold
measured by the dynamic plantar aesthesiometer and a
von Frey threshold <5.4 g are included in the treatment
groups. Allodynic rats are randomised to form three
treatment groups to be treated intraperitoneally (i.p.)
with test compound A at a low dose, at a high dose and
a vehicle control, respectively. An 8-day-long repeated
dose regimen is utilised with daily treatments and the
anti-allodynic eﬀect is determined on Day 1, Day 4 and
Day 8 of treatment at 30 and 60min after the injection.
At the end of the study animals are euthanised. In this
study, no analgesia will be provided as this would inter-
fere with the study results.
Consideration of specific refinements and humane
end-points.
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make
it worse? How will suffering be reduced to a minimum?
Adverse effects
Methodology and interven-





tion to the paw up to the
sensory threshold or the
cut off value
Using von Frey hairs and
dynamic plantar
aesthesiometer
Use of cut off values of
stimulus strength
Rats with low baseline
threshold are excluded
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Initial prospective assessment. Interventions
involved in this model individually do not exceed mod-
erate severity. If the surgery is carried out with proper
skills and, consequently, no complications occur, this
part of the procedure is within the moderate category.
Following surgery, careful monitoring allied to clear
end-points will ensure no animals exceed moderate
severity.
A prospective severity classiﬁcation of MODERATE
is therefore appropriate.
Could the severity classiﬁcation be MILD?
No. As the prolonged pain resulting from these
interventions renders the model moderate, and
assessment of the pain itself is the objective of the
study, it is not possible to conduct this procedure
within a MILD classiﬁcation.
Clinical observation/scoring system. Animals were
carefully monitored from surgery until the end of the
procedure. Two nociceptive assays were applied to
measure latency of hind feet withdrawal: (1) von Frey
hairs of diﬀerent stiﬀness were used to determine the
one that evoked a hind paw withdrawal; (2) dynamic
plantar aesthesiometer. During the assays no additional
agent was used.
Continued
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make
it worse? How will suffering be reduced to a minimum?
Adverse effects
Methodology and interven-
tions to minimise severity End-points
Effect of surgery:
Pain in the affected leg,
sparing limb from
weight bearing.
Motor deficit in the
affected paw
Soft bedding in home cage;
careful handling of the
animal
Ensure plenty available
space to allow animals
to rest without contact
from other animals.
Animals showing major
motor deficit in the
affected limb or signs of
autotomy, beyond nail
chewing on the affected
paw are euthanised.
(extremely low probability





















Animals failing to develop
the pre-determined
degree of allodynia after











Possible side effect of test
drugs
Competent personnel










Euthanasia at the end of
the procedure
Doses of the test com-
pound are not expected
to cause adverse
effects, but animals will
be killed if severe clin-
ical signs are noted.
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An example of an observation sheet and a sample
score sheet to help monitor the clinical condition of
animals throughout the procedure are included at the
end of this example.
Results and assessment of actual severity. All ani-
mals, except one in the vehicle treated group, recovered
from surgery with no unexpected complications, due to
the intensive peri-operative support provided.
Nociceptive assays indicated that mild or moderate
pain was experienced.
Vehicle group
1/10 animals did not recover from surgery. NON-
RECOVERY
1/10 animals showed signs of automutilation and
was euthanised. MODERATE severity.
1/10 animals reached a humane end-point and was
euthanised. MODERATE severity.
7/10 animals showed a poor performance in the
nociceptive assays and the behavioural tests compared
to treated animals. However they did not show any
other clinical eﬀects and maintained body weight.
Clinical score was similar to treated animals after the
surgery. These animals developed moderate neurologi-
cal-locomotor deﬁcit, and showed a gradual reduction
in clinical score over time, possible resulting from their
ability to compensate and adapt to long term neuro-
logic deﬁcits. MODERATE severity.
Treatment groups
10/10 animals treated at lower doses showed mild
improvement in motor function, together with an
improvement in clinical scoring. The agent had anti-
allodynic eﬀect, compared to vehicle. No speciﬁc side-
eﬀect was reported. MODERATE severity.
10/10 animals treated at higher doses showed signiﬁ-
cant improvement in motor function, together with an
improvement in clinical scoring. The agent had clear
anti-allodynic eﬀect, compared to vehicle. No speciﬁc
side-eﬀect was reported. MODERATE severity.
Although animals in the treated groups experienced
less pain, due to the surgery and prolonged allodynia




Severity is assessed using a cumulative score from a
combination of general clinical observations (body-
weight, appearance, behaviour, cage environment,
food and water intake, body function) together with a
procedure-speciﬁc evaluation.
General clinical signs Score
Appearance
5–10% weight loss 1
11–15 % weight loss 2
16–20% weight loss 3
20%þ weight loss HEP




Rapid, slow or deep breathing – slight 1
Rapid, slow or deep breathing – moderate 2
Rapid, slow or deep breathing – marked 3
Food and water intake
Not drinking up to 10% of body weight per 24 h 1
Not drinking at all 3
Reduced food intake 1
Anorexia 3
Behaviour
Slightly decreased mobility 1
Markedly decreased mobility 2
Significant mobility problems 3
Immobility >24 h HEP
(continued)
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Score 0–5 plus surgery¼MODERATE
Either 2 scores of 3 in any of the categories or a total
score of 12 and above¼HEP
Note: that as surgical complications are generally
noted in the immediate post-op recovery period, close
monitoring and expert, empathetic judgement are
essential during the ﬁrst 24 h to ensure that adverse
eﬀects are identiﬁed and actions taken to address
these. Animals are humanely killed if their suﬀering
exceeds of the moderate category.
1 – Review frequency of monitoring.
4 – Provide appropriate supplementary care, e.g.
mash and additional ﬂuids
Dehydration/diarrhoea: Ringer Lactate or regular
serum
Abdominal dilation (ascites): draining for pressure
reduction
Weight loss: soft food
5 – Review progress with vet
Either 2 scores of 3 in any of the categories or a total
score of 12 and above¼HEP
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Stroke – efficacy of a novel therapeutic
agent on intraluminal thread MCAO model
in the marmoset
General context
Stroke is deﬁned as loss or alteration of normal body
function that results from an insuﬃcient supply of
blood to part of the brain. Despite better understanding
of the pathophysiology of vascular brain injury, an
eﬀective treatment for stroke remains an important
unmet medical need, and research is on-going to ﬁnd
appropriate preventive and therapeutic measures.
Three diﬀerent types of stroke can be seen in human
patients: ischaemic, intra-cerebral haemorrhage and
subarachnoid haemorrhage, but most of the animal
models currently available are based on the ischaemic
type. Stroke models, by their very nature, represent a
challenge from the perspective of animal welfare. Good
interactions and communication between all individ-
uals involved in the scientiﬁc procedures, (veterinar-
ians, investigators, animal technologists and care
staﬀ), are critical to ensure that there is adequate bal-
ance between achieving a valid model in this research
area and minimising animal suﬀering.
Stroke is routinely induced in rodents and non-
human primates by temporarily or permanently occlud-
ing the middle cerebral artery (MCAO model).This
‘MCAO’ model aims to reproduce experimentally the
focal cerebral ischemia that occurs in stroke, and it has
been extensively used to study the mechanisms of
injury, to identify potential targets and to test putative
neuroprotective agents.
Continued
General clinical signs Score
Tense and nervous on handling 2
Markedly distressed on handling, e.g. shaking, vocalising, aggressive 3
Procedure-specific indicators Score
Wound healing
Wound edges are smoothly closed, no sign of inflammation 0
Wound edges are slightly swollen and erythematous 1
Wound is clearly infected/partially opened 3
No improvement of wound infection to topical and systemic
treatment/wound is completely opened
HEP
Status of the operated limb
Slightly reduced weight bearing 1
Marked gait impairment (lameness) 2
Severe gait difficulty/paw is often held in a constant elevated position 3
Major motor deficit >24 h postop/signs of autotomy HEP
TOTAL
HEP: humane end-point
Smith et al. 31
In a standard study design, the animals are trained
to perform certain behavioural tests prior to the
MCAO procedure. During the therapeutic time
window, established according to the mechanism of
drug action and objective of the study, animals are
given the test compound. The outcome analysis
should include information on infarct size, mortality
rate, frequency of complications (e.g. subarachnoid
haemorrhage), together with functional and neuro-
logical evaluation to monitor progress. Serial magnetic
resonance imaging (MRI) has proven to be a powerful
tool to gain information on variation of infarct size
over time, but can also provide additional information
on blood ﬂow or metabolic state. Histological, bio-
chemical and molecular end-points can also be
included.
There are various behavioural tests that may be
applied to stroke models. The simplest tests include
neurological scoring systems, which assess global
neurological status, and limb placing tests, used to
measure motor reﬂexes. These are generally used to
assess animals in the acute post-stroke phase. In long-
term studies, more complex tests may be used to assess
sensory and motor functions (e.g. bilateral sticky label
test, beam walking, rotarod or staircase) and cognitive
functions such as memory (e.g. passive avoidance tests,
or evaluations of learning strategies).
It is good practice to perform a group of behavioural
tests, including at least one for each phase (acute and
long-term), so as to gather comprehensive information
on the impact on sensory, motor and cognitive func-
tions. These tests have to be carefully chosen to capture
any eﬀects of the putative therapeutic strategies.
Detailed descriptions of each of these behavioural
tests, including training schedules, are not included
here, but for a comprehensive review and discussion
of their use see Schaar et al.1
Many recent recommendations for preclinical inves-
tigations designed to develop stroke therapies recom-
mend the use of higher order species such as non-
human primates in addition to rodent models.2–5 The
common marmoset (Callithrix jacchus) may be con-
sidered the species of choice to study the pathophysi-
ology and the treatment of cerebral ischemia.
Compared with rodents, this primate is closer to
humans in term of cerebrovascular system, brain
metabolism, grey-to-white matter ratio and has a
richer behavioural repertoire. In addition, compared
to old world monkeys, they are easier to handle,
which is advantageous for behavioural testing and post-
operative care management. The location and anatomy
of the MCA in the marmoset have historically restricted
the approaches used in rats and thus a more invasive
surgical model was developed that included the turning
of a large bone ﬂap to access the brain and the MCA.
Nevertheless, more recently the intraluminal thread
approach has also been described in the marmoset.6
The intravascular approach presents a number of
advantages compared to previously used methods,
and should be considered a clear reﬁnement. In particu-
lar the absence of craniotomy and the comparative
non-invasiveness results in fewer adverse eﬀects (e.g.
severe disability/mortality) encountered in the post-
operative period.
As in rodents, the ﬁrst 48 h post-surgery are critical.
The animals will have diﬃculties caring for themselves,
and typical impairments can include left arm hemipar-
esis, abnormal grasp reﬂex, left-sided neglect, nystag-
mus and rotation of eye.7 Generally, after 3–7 days the
animals are capable of self-care and can return to their
home cage. Gradually (around 2 weeks post-surgery),
they will recover the majority of motor abilities and will
be able to freely jump and climb around their cages.
Illustrative procedure
Study design. In this example, on eﬃcacy of a new
compound, six male and six female laboratory-bred
marmosets (Callithrix jacchus) will undergo 3 h-transi-
ent MCAO using the intraluminal ﬁlament technique
under general anaesthesia. Before surgery, marmosets
will be trained and tested on a number of neurological
tests, which assessed general neurological function,
motor ability, and spatial awareness. Immediately
after tMCAO, marmosets will receive a bolus of
saline (n¼ 6) or test compound A (n¼ 6), and osmotic
mini-pumps will be implanted subcutaneously, provid-
ing 48-h saline or drug infusion. Sensory-motor deﬁcits
will be assessed weekly up to 45 days after MCAO, and
MRI scans performed under general anaesthesia, at 1 h,
D8 and D45. Animals will be killed 46 days after
MCAO.
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Consideration of specific refinements and humane
end-points.
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might it make













voluntarily by the ani-
mals and will not cause
pain, distress or lasting
harm
All tests are performed in
the modified home cage
Typically, a maximum time
to perform the
requested task is set,




excluded from the study
Under general anaesthe-
sia, transient (3 h)
occlusion of the MCA
using an intraluminal
thread advanced via the
common carotid artery.


















alysis, severe head tilts,
seizures









and poor motility, gen-



























tion and wound care
Providing easy accessible
food and water during
the recovery period, or
additional food (mash,
liquid) and assistance
with feeding if neces-
sary; rehydrate (e.g. via
saline injection) if
necessary
Animals will be humanely





 Failing to fully recover
from anaesthesia
 Signs of unexpected
surgical complications
 If animal’s bodyweight
loss exceeds 20% pre-
surgical weight, despite
additional feeding and/





Pain and discomfort asso-
ciated with surgical
Animals will be closely
observed for adverse
Animals will be humanely
killed if any severe side
(continued)
Smith et al. 33
Initial prospective assessment. This model is con-
sidered SEVERE because of the surgical procedure
involved and the deleterious eﬀects of the MCA occlu-
sion on the welfare of the animal, especially during the
ﬁrst week. Nevertheless, intensive post-operative care in
the ﬁrst 48 h up to 7 days, and close monitoring of the
subsequent phase can greatly contribute to reduce
negative impact on animal welfare. From the experi-
mental point of view, attention to reﬁnement and
standardisation of the individual steps in the procedure
can lead to reduced incidence of complications and
variability, and consequently better quality of the
data obtained and therefore a reduction of the
number of animals required.
A clinical score sheet should be agreed upon by the
researcher, veterinarian and animal technologists to set
up criteria for monitoring and euthanasia; it will need
to include the neurological score, together with other
clinical criteria such as body weight, ability to care for
themselves or reaction to stimulus.
Could the severity classiﬁcation be MODERATE?
Experience/training of personnel involved, veterin-
ary supervision, and intensive care in the early post
MCAO period together with agreed end points can sig-
niﬁcantly reduce the incidence of negative eﬀects
experienced by the animals.
Clinical observations/scoring system. Animals are
very carefully monitored in the post-operative period.
Analgesia and local supportive therapy are provided.
An example of a combined neurological/clinical
scoring system which is used to help monitor the clin-
ical condition of the animals throughout the procedure
is included at the end.
Results and assessment of severity. All animals
recovered from surgery with no unexpected complica-
tions. Clinical scoring in all animals was similar in the
ﬁrst 48 h after MCAO, and all of them received inten-
sive peri-operative support. No signiﬁcant ipsilateral
deﬁcit was observed after induction of ischemia in nei-
ther control nor treated animals. A partial recovering
Continued
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might it make





ous implantation of a
mini-pump under gen-
eral anaesthesia (as
part of the MCAO surgi-





No adverse effect expected








formed daily during the
first week post-MCAO,





Animals may find the tasks




indicators of anxiety or
distress
Animals will be continu-
ously observed by
experienced staff
Typically, a maximum time
(cut-off) to perform the
requested task is set,
and a final score is given
Longitudinal imaging (MRI)
under anaesthesia at
1 h, 8 and 45 days after
MCAO
Repeated anaesthesia




blood gases) on stroke
outcome
Use of appropriate anaes-
thetics and analgesics





Animals failing to fully
recover from anaesthe-
sia will be euthanised
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of contralateral neurological deﬁcit was observed in all
animals.
– All six vehicle-treated animals developed moder-
ate contralateral neurological deﬁcit, together
with a poor performance in the behavioural tests
compared to treated animals. Clinical score was
nevertheless improving over time possible result-
ing from their ability to compensate and adapt to
long term neurologic deﬁcits
Assessment: SEVERE
– 2/6 treated animals developed moderate contralat-
eral neurological deﬁcit, together with a poor per-
formance in the behavioural tests compared to
treated animals. Clinical score was nevertheless
improving over time, possible resulting from
their ability to compensate and adapt to long
term neurologic deﬁcits
Assessment: SEVERE
– 4/6 treated animals showed a signiﬁcant improve-
ment in neurological scoring after 48 h post-
MCAO, together with an improvement in clinical
scoring.
Assessment: MODERATE
In conclusion, 8 animals were considered as




Severity assessment is performed by a combination of
general clinical observations (bodyweight, appearance,
behaviour) together with a procedure-speciﬁc neuro-
logic evaluation. The neurological score used was a
modiﬁed version of that described by Bihel et al.
where absence (score 0), moderate presence (score 1)
or presence (score 2) of a number of abnormal move-
ments/postures are evaluated separately for each body
side (i.e. ipsilateral and contralateral to MCAO
lesion).6
In addition, a separate neurological scoring will be
carried out. The limbs will be assessed independently,
with the maximum hemilateral score being 10. In con-
trol animals, a high scoring (up to10) is expected in the
contralateral side of the body during the ﬁrst week after
MCAO, gradually recovering in the subsequent weeks.
No signiﬁcant ipsilateral deﬁcit is expected (as this
would mean the ischemic area is too large).
Each limb will be assessed and scored separately;
severe contralateral neurological deﬁcit together with
poor clinical conditions are expected during the ﬁrst
week post-MCAO while ipsilateral neurological
damage should be very limited/absent.
The neurological score for each limb will be added to




5–10% weight loss 1
11–15 % weight loss 2
16–20% weight loss 3
20%þ weight loss HEP







Slightly abnormal gait 1
Markedly abnormal gait 2
Significant mobility problems 3
Immobility >24 h HEP
Tense and nervous on handling 2
Markedly distressed on handling,















Hind limbs slipping or
dangling under the
perch, at rest or
during movement
0 1 2
Hand crossing the chest 0 1 2
Head tilting (before and
after stimulation)
0 1 2
Lack of reaction to
visual stimulus
0 1 2
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Week 1 post MCAO
It is well known that immediately after MCAO, a
high cumulative scoring is to be expected with a pro-
gressive improvement over the ﬁrst week post- surgery.
During this critical period, animals will receive inten-
sive care and will be frequently monitored under the
supervision of a veterinary surgeon. In particular, the
ﬁrst 48–72 h are key to identiﬁed potential surgical
complications and ensure that adverse eﬀects are iden-
tiﬁed and actions taken to address them in a timely
manner.
 22 – HEPtpb 1pc
Weeks 2–6 post MCAO
1–10 – monitor regularly, evaluate together with the
clinical score
10–20 – monitor frequently, provide care if not able
to care for itself, evaluate clinical scoring and team to
review all experimental data available (i.e. MRI, behav-
ioural tests) to rule out unexpected complications, such
as brain haemorrhage, oedema, etc.
 20 – HEP
Example of an Individual observation sheet
(Days 0–4)
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Cardiovascular evaluation of novel
therapeutics – telemetered dog model
General context
Any medical drug to be marketed will need to prove
eﬃcacy but also safety. Therefore, even compounds
intended for use in very diﬀerent areas
Day 0 1 2 3 4
Appearance
Body weight (g) (score) 340 (1) 305 (3) 320 (2) 323 (2) 335 (1)
Coat unkempt/piloerection 1 1 1 1 1
Behaviours
Gait 3 3 3 3 3
Response to handling 0 0 2 0 0
Total clinical score 4 7 8 5 5
Total neurological score 15 14 14 10 10










*‘Lesion volume’ (assessed using MRI) is included for the investigator to fill in at the end of the study. This data can then be correlated
with clinical and behavioural observations to enable further refinement of monitoring, animal care and procedures.
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(e.g. neuropharmacology) will have to be evaluated for
their potential cardiovascular eﬀects.
Cardiovascular eﬀects of compounds can be tested in
a variety of ways: in invasive terminal procedures on
anesthetised animals, in animals which are momentarily
restrained and externally equipped with monitoring
devices or in freely moving animals previously
implanted with monitoring devices (telemetry systems).
Over the past decades, telemetry systems have been
increasingly applied in drug research and development
for measurement of physiological and bioelectrical vari-
ables (e.g. blood pressure, heart rate, ECG).1 The
absence of tethering, handling and restraint during
measurement provides a unique opportunity to study
laboratory animals without additional stress or physio-
logical disturbance (anaesthesia) during a longer period
of time. In between measurements, animals can more-
over be group-housed.
Telemetry can also enable reduction in animal num-
bers. Firstly, because telemetry systems are stable for
months (and possibly even years), animals can be used
as their own controls, reducing data variability and
consequently the number of animals needed per treat-
ment group. Secondly, telemetry provides an ability to
continuously record a number of variables so that there
is a signiﬁcant increase in the amount of data that can
be obtained from a given number of animals, compared
to the use of conventional methods. Thirdly, in the
absence of potential stressors, such as restraint or exter-
nalised catheters, the quality of data obtained is
improved. Telemetry systems can also provide indica-
tors of animal wellbeing to help implement earlier,
more humane end-points.2 Telemetry thus is widely
regarded as beneﬁting science while minimising
impact on animal welfare. However, the requirement
for appropriate surgical training should not be under-
estimated, as this has a direct impact upon animal wel-
fare. A sound basic and advance training in
experimental surgery and good working knowledge of
the devices are absolutely essential before progressing
into implant insertion
Illustrative procedure
Study design. In this example, three pre-selected male
beagle dogs (suitable temperament) will be used.
Animals will act as their own control.
After overnight fasting, animals will be anesthetised.
Telemetry devices allowing for continuous measurement
of body temperature and cardiovascular parameters
(ECG, blood pressure) will be surgically implanted. The
implantation of these telemetric devices is a surgical pro-
cedure not invading body cavities, as the emitter is not
implanted intraperitoneally, but in an inter-muscular
pouch. The catheter is inserted in the femoral artery
and further advanced into the aorta. ECG electrodes
are tunnelled subcutaneously. The discomfort provoked
is linked to the implantation and the surgical wounds
created, and the animals’ need to be anaesthetised.
During the 3 week recovery period, animals will be
trained to be socially isolated for 2 h (e.g. telemetric
recording).
After recovery, the procedure calls for continued
use: animals will be used weekly (one day with vehicle,
and another with compound) to evaluate cardiovascu-
lar eﬀects of the novel therapeutic agent at two diﬀerent
dose levels. The ﬁrst treatment will consist of vehicle
administration, followed by administration of the novel
pharmaceutical agent. In-between recordings, animals
will be socially housed. A minimal wash-out period will
be allowed between test sessions (as determined by PK
studies).
The study is intended to assess the potential cardio-
vascular eﬀects of novel agents at proposed thera-
peutics doses.
At the end of the experiment, animals will be socially
housed, while awaiting possible re-use.
Consideration of specific refinements and humane
end-points.
Initial prospective assessment. The procedure is clas-
siﬁed as MODERATE as it requires anaesthesia and
surgical intervention.
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make it worse
Adverse effects
How will suffering be reduced to a minimum
Methodology and interven-
tions to minimise severity End-points
Pre-surgical prepar-
ation of the animal











Decision to humanely kill the
animal during surgery if
(continued)
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The administration of the compound is expected to
have no clinical eﬀect on the animal. However, admin-
istration of the compound is MILD, as it involves injec-
tion according to Good Veterinary Practice.
Could the severity classiﬁcation be MILD?
No: the procedure involves anaesthesia and surgery;
thus classiﬁcation is MODERATE.
In the case of re-use of previously implanted animals
that have been used in another project, the simple
administration and evaluation through the use of tel-
emetry of test compounds at therapeutic dose levels,
and as no restraint is involved (freely moving) the pro-
spective severity is to be classiﬁed as MILD
Could the severity classiﬁcation be SEVERE?
Yes, if the compound tested at doses administeredwould
have toxic eﬀects (cardiovascular or other). This would def-
initely mean that the ﬂow chart of testing is not accurate, as
a model of telemetry is deﬁnitely not intended to evaluate
toxic doses, but rather clinical/therapeutic doses of com-
pounds. The study design would need to be reviewed.
Clinical observation/scoring system. Animals are
carefully monitored at every step of the procedure. A
speciﬁc anaesthesia sheet, as well as a clinical observa-
tion sheet, are developed, and included at the end of
this example. During techniques, any clinical observa-
tion is recorded daily. During the wash-out periods,
animals are observed and weighed at least weekly.
Results and assessment of actual severity. Three
dogs underwent the procedure. All recovered from sur-
gery without any complication, no cardiovascular side-
eﬀects were observed in any of the animals at any of the
doses tested.
The three animals were considered to have experi-
enced MODERATE severity.
Continued
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make it worse
Adverse effects
How will suffering be reduced to a minimum
Methodology and interven-
tions to minimise severity End-points
Potential adverse effects































Any animal with clinical signs of
infection will be examined,
treated and temporarily
excluded from the study
Administration of test
compound (i.v., s.c.,













Blood pressure, ECG and
body temperature are
continuously monitored
in freely moving animal,
housed in pen equipped
with telemetry receiver.
Between studies animals
are group housed and
observed daily,
Body weight is recorded
weekly.
In case of prolonged side effects
after test compound treat-
ment: possibly treat and allow
animal longer wash-out
period and clinical check-up
before new dosing and deci-
sion on possible euthanasia.
End of battery life: animal is
either proposed for re-use as
blood donor, or if competent
authorities authorise,
explanted and depending on
vet examination proposed for
rehoming or proposed for re-
use as blood donor.
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At the end of the procedure the animals were again
socially housed. The level of severity was
MODERATE, due to the surgical implantation ani-
mals underwent, but the general state of health has
been fully restored. No cumulative severity was
observed due to administration of the novel therapeutic
agent under evaluation. Therefore it is considered that
animals may be re-used in future MILD, MODERATE
or Non-recovery procedures pending an appropriate
wash-out period and after positive veterinary advice.













































*: Administer analgEsics and antibiotics according to procedure







Observations and other actions Visa
Batch n° of telemetry device
Post-op follow-up sheet
 Micro-chip:                    Dog n°:
        Dog Name:
Researcher:
         Batch: Date surgery:
gk:thgiewydoB:etad lavirrAdI erudecorP





Score behaviour as 0, +, ++, +++
Observe Salivation, Myosis, Mydriasis, Defaecation, Miction, Posture of animal, Sedation, Locomotor activity, Rigidity, Vocalisation, etc.
Describe any unexpected abnormalities and contact the Veterinarian
Also note time quantity and containers of blood samples obtained
gk:thgiewydoB:etad lavirrA:dI erudecorP
Start/end of 
telemetric recordings Behavioural observations Other acons
Batch n° of telemetry device
Study follow-up sheet
 Micro-chip:
      Dog n°:
Dog Name:
Researcher:
         Batch: Date surgery:
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Evaluation of the efficacy of novel
antiarrhythmic substances – rabbit model
of atrial fibrillation using implanted
mini-pump for administration of
substances
General context
Paroxysmal atrial ﬁbrillation (AF) is a condition in
which an irregular heart rhythm occurs periodically.
The heart returns to its normal sinus rhythm on its
own in a few minutes, hours or days. People who
have this type of AF may have episodes every day,
or only a few times a year. When these episodes
begin and end is usually unpredictable, which can
be very unsettling. About 1 in 4 people with parox-
ysmal AF eventually develop the permanent form of
the condition.
The causes of paroxysmal AF aren’t always
known. Although AF can occur in patients without
evident heart disease, organic heart diseases, such as
congestive heart failure and mitral valve disease, are
involved in about half the cases of paroxysmal AF
and 80% of persistent or permanent AF. People with
paroxysmal AF appear to be at just as high a risk of
developing blood clots as those with chronic AF.
However, the beneﬁts of blood-thinning medications
have not been shown to be as eﬀective in people with
paroxysmal AF as those with chronic AF. AF is a
common arrhythmia and a potent risk factor for
cardio-embolic stroke. There is evidence for many
ion current changes in studies of the ionic properties
from atrial tissue of patients with AF, and this is the
reason that ion channel blockers require to be
investigated.1,2
The development of numerous animal models of AF
with clinically relevant disease paradigms has been a
major advance over the past years. Models have been
developed in rats, dogs, goats, sheep and more recently
in genetically altered mice.3 The severity and invasive-
ness of the model will depend on the underlying causes
studied.
Screening based on electrophysiological, ionic, and
molecular mechanisms in in vitro models allow identiﬁ-
cation of potential eﬃcacy of compounds, which are
then evaluated in in vivo models. The ideal animal
model for drug testing should be simple, stable, inex-
pensive, clinically relevant, allow for reliable sustained
AF production (for testing drug-induced termination)
and eventually allow for easy conversion to sinus
rhythm (for multiple dose studies). The example pro-
vided here concerns a surgical model which has proven
good reproducibility in producing AF, together with
minor clinical discomfort to the animal.
Illustrative procedure
Study design. In this example, 10 large adult male
New Zealand White (NZW) rabbits (n¼ 5 per dose
group (saline control and test substance)) will be
used. Based on power analysis from previous data (pre-
liminary studies) this was determined to be the minimal
number of animals required per sample size.
In order to allow the test compound to be present as
a preventive treatment in a steady state level, a subcuta-
neous mini-pump will be implanted which allows deliv-
ery of the compound for 21 days. This allows not only
for continuous diﬀusion of the drug in the animal’s
body (thus preventing peaks of drug distribution) but
also minimises disturbance of the animal for drug
administration (which can momentarily provoke sup-
plementary changes in heart frequency and lead to
spontaneous AF).
Under the same anaesthetic procedure, bipolar elec-
trodes will be implanted on the left atrium and con-
nected to an electrical stimulator. The electrical
stimulator will be contained in a jacket. Animals will
be habituated to the jacket before surgery.
A post -operative period of 7 days will allow the
animals to fully recover from the surgery. Thereafter,
implanted electrodes will be stimulated daily for 14 con-
secutive days. This allows a graded stimulus, gradually
increasing heart rate and provoking paroxysmal AF.
This will involve occasional handling and immobilisa-
tion of the animal in order to modify stimulation
parameters.
14 days later, the animals will be terminally anaes-
thetised. Once hemodynamic parameters are stable, AF
will be provoked by a ﬁxed time period of electrical
stimulation and hemodynamic parameters and bio-
logical markers will be measured.
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Consideration of specific refinements and humane
end-points.
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make it
worse? How will suffering be reduced to a minimum?
Adverse effects
Methodology and interven-
tions to minimise severity End-points
Single housing (as adult
males and surgically
equipped)
Habituation of the animals
to the jacket& weighted
backpack
May cause some distress





If animal fails to acclima-





agent and placement of
bipolar electrodes on










Pain and discomfort asso-
ciated with surgery
Therapeutic substance not









drugs during surgery, i.v.
perfusion of saline
Non- pharmacological control




Analgesia will be provided
routinely, and continued as
indicated.
Use of very experienced
personnel.
Decision to humanely kill






Period of recovery (7 days)
and thereafter continu-
ous stimulation of the
implanted electrodes










drug diffusion can pos-
sibly cause discomfort
due to localisation of
mini-pump and/or diffu-
sion of drug
Heart frequency is grad-
ually increased. AF may




Appropriate housing and a
jacket will prevent the
animal from injuring itself
or interfering with the
electrodes/wound site (e.g.
large and high cage).
Daily massage to prevent
adhesions of the mini-
pump.






matory drugs suitable for
species for at least 2 days




Animals will be humanely
killed if weight loss
exceeds 20% of initial
body weight in less than
48 h.




(clinical signs of dis-
tress; failure to return
to normal by 48 h post-
op
Animals with clinical signs
of infection will be
examined and treated
(continued)
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Initial prospective assessment. The study is intended
to assess the eﬃcacy of novel therapeutic agents in pre-
venting/minimising occurrence of AF following elec-
trical stimulation of the left atrium.
The s.c. implantation of a mini-pump is a very fast
procedure; only takes a few minutes for an experienced
person. The thoracic surgery is an invasive procedure.
There is a need to anaesthetise the animal and the sur-
gery may certainly provoke some pain and discomfort.
The cardiac stimulation itself does not seem to provoke
any pain, no visible discomfort: animals do not seem to
react to increased heart frequency when this is done in a
slow and progressive manner.
A prospective severity of MODERATE is deemed
appropriate.
Could the severity classiﬁcation be MILD?
No; the thoracic surgery will provoke pain and dis-
comfort, which however is minimised by pain allevi-
ation and best practice surgical techniques.
This procedure involves major surgery, even the
implantation of the mini-pump alone would be a pro-
cedure which must be carried out under anaesthesia.
Could the severity classiﬁcation be SEVERE?
If for whatever reasons no adequate analgesia or
post-operative analgesia would be given this procedure
could potentially provoke severe pain.
If cardiac stimulation would not be gradual, it might
provoke spontaneous AF, which may lead to spontan-
eous death of the animal and thus should be classiﬁed
as SEVERE. This is rare, and should with appropriate
progressive stimulation only occur very rarely
Clinical observation/scoring system. Animals are
very carefully monitored at every step of the procedure
using a speciﬁc anaesthesia log and a clinical observa-
tion sheet. In the post-operative period, analgesia and
local supportive therapy are provided as necessary and
recorded on the individual clinical observation sheet.
Sheets are ﬁlled out daily and include recordings of
bodyweight, body temperature, clinical signs, standard
post-operative treatments, any other treatments.
Stimulations and reactions to it are also recorded.
Examples of observation sheets are included at the
end of this example
Continued
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make it
worse? How will suffering be reduced to a minimum?
Adverse effects
Methodology and interven-
tions to minimise severity End-points
on skin wounds. Post-
operative monitoring with
daily clinical scoring sheet
(body temperature, body
weight, food intake, wound
care, etc.)
Animals are habituated to
weight of backpack.
Clinical daily follow up of
animals
Housing and handling under
non-stressful conditions
Terminal anaesthesia (with
provoked AF) 14 days
later
AF may occur spontan-
eously,
Presents as sudden death;












wise at end of 3 h
measurement during
terminal procedure
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Results and assessment of actual severity. Ten ani-
mals underwent the procedure. All recovered from sur-
gery without complications. One animal in the saline
control group was found dead shortly after the ﬁrst
electrical stimulation. All other animals underwent the
terminal anaesthesia during which eﬃcacy of the thera-
peutic agent was evaluated versus vehicle. Severity
assessment for the ﬁve saline-treated animals:
- 1 out of 5 rabbits was found dead at D11 (ﬁrst
electrical stimulation): SEVERE
- 4 out of 5 completed the terminal anaesthesia pro-
cedure: MODERATE
- 5 compound treated animals were used. All 5 com-
pleted the terminal anaesthesia procedure:
MODERATE
Example of post-operative follow-up sheet
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Determination of ecotoxicity of a test
substance – bioconcentration flow-through
fish test
General context
The bioconcentration test aims at determining the
bioaccumulating potential of a chemical in tissues of
ﬁsh, when triggered by (a.o.) its octanol-water parti-
tioning coeﬃcient. This is a legal requirement for all
chemicals when exposure of the aquatic environment
is possible. A study can be conducted with waterborne
exposure; this will provide a bioconcentration factor
(BCF, ratio of concentration in ﬁsh divided by concen-
tration in water). The study may also be conducted with
dietary exposure (e.g. when the substance is very poorly
soluble in water); this will provide the biomagniﬁcation
factor (BMF, ratio between concentration in ﬁsh
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The BCF or BMF is used in the assessment of the
persistence, bioaccumulation and toxicity (PBT) and
very persistent and very bioaccumulative (vPvB) cri-
teria, and is used for the environmental risk assessment
for the aquatic food chain (i.e. water – ﬁsh – top preda-
tors, such as birds and mammals). If a substance is
bioaccumulative it will accumulate in living organisms
once it enters the environment, which may lead to
adverse eﬀects higher in the food chain. A substance
for which all criteria for PBT and/or vPvB are fulﬁlled
will be identiﬁed as a PBT/vPvB substance. Substances
identiﬁed as being PBT or vPvB are considered candi-
dates for substitution, which means that they should be
replaced by substances that are not PBT/vPvB if
possible.
A PBT/vPvB assessment is required for all sub-
stances (i.e. industrial chemicals, agrochemicals, bio-
cides and human and veterinary drugs). Though there
are some QSARs available, these are not always suit-
able, depending on the molecular structure or physico-
chemical characteristics of the chemical. Furthermore,
QSARs will only estimate the BCF of the unchanged
chemical, while a study in ﬁsh allows for the determin-
ation of degradation products and elimination time
upon transfer to uncontaminated water.
Fish species used in the test may involve: carp
(Cyprinus carpio), zebra-ﬁsh (Danio rerio), fathead
minnow (Pimephales promelas), bluegill (Lepomis
macrochirus) or rainbow trout (Oncorhynchus mykiss).
Illustrative procedure
Study design. The study is performed based on the
OECD guidelines for testing of chemicals, Guideline
No. 305: Bioaccumulation in Fish: Aqueous and
Dietary Exposure, October 2012.1 The procedure is
designed to meet the test methods prescribed by
Commission Regulation (EC) No 440/2008 of 30 May
2008, Part C: Methods for the determination of eco-
toxicity, Publication No. L142, C.13
‘Bioconcentration: Flow-through Fish Test’.2 The ﬁsh
are exposed during an uptake phase of 28 days and a
depuration phase of 56 days. The duration of both
phases may be changed based on the course of uptake
and/or depuration. During the uptake phase a group of
ﬁsh is exposed to the test substance at one or more
chosen concentrations. The numbers of ﬁsh per test
concentration are selected such that a minimum of
four ﬁsh are available at each sampling point. They
are then transferred to a medium free of the test sub-
stance for the depuration phase. The ﬁsh are kept in
tanks with a continuous supply of water, to which the
test substance is added during the uptake phase. The
water volume should be replaced at least ﬁve times per
day. Non-toxic concentrations of test substances are
used. Radiolabelling of the test substance may be
used for analytical purposes. Water samples are taken
prior to and during uptake and depuration phase. Fish
are selected for tissue sampling following euthanasia at
sequential time points during the uptake phase (e.g. 1,
3, 7, 14, 21 and 28 days) and the depuration phase
(30, 35, 42, 56 and 84 days); and for lipid extraction
at 0 or 28 days of exposure. Weighing is per-
formed before test and post-mortem; sampling of ﬁsh
during test and post-mortem. Four or more ﬁsh are
needed per sampling point and per test concentration.
A total number of 130 rainbow trout were used and
exposed to two diﬀerent concentrations of a test sub-
stance: 32 ﬁshes will be used for the control group
(1 replicate) and 49 ﬁshes for each test concentration
(2 replicates).
Consideration of specific refinements and humane
end-points.
What does this study
involve doing to
the animals?








Fish to be used for test are
captured, weighed and
measured
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Initial prospective assessment. Animals are only
expected to experience MILD discomfort based on
exposure to non-toxic concentrations of test substance,
and the use of good practice for handling and
euthanasia.
A prospective severity classiﬁcation of MILD is
therefore appropriate.
Could the severity be MODERATE?
Normally not, as during the bioaccumulation phase
only slight or no adverse eﬀects, and thus only MILD
discomfort are expected based on use of non-toxic dose
concentrations, good practice handling and euthanasia
methods. If contrary to expectations clinical signs indi-
cating moderate severity are observed, an informed
decision is made on the follow-up of the experiment,
e.g. euthanasia of the animal based on humane end-
points, intensiﬁed monitoring or need for change of
prospective severity assessment of similar experiments
and notiﬁcation to CA.
Clinical observation/scoring system. Animals are
monitored for mortality/viability and any adverse
eﬀects daily. Any clinical score sheet and observation
procedure should be agreed upon by the researcher,
veterinarian and animal technologists to set up criteria
for monitoring and timely euthanasia (humane end-
points).3–5 Temporary use of light to improve observa-
tions is possible but should be limited. Fish are
observed for adverse eﬀects and mortality after 2–4 h,
and for mortality or possibly more adverse eﬀects for
possible implementation of humane end-points at the
end of the day. Then following mornings, the ﬁsh are
checked for any mortality, and for mortality and any
(more) adverse eﬀects on the observation moments, and
at the end of the day. An example of the clinical obser-
vation and scoring system used to help monitor the
clinical condition of animals throughout the procedure
is included at the end of the example. Unless typical
clinical signs or abnormalities (e.g. typical swimming
Continued
What does this study
involve doing to
the animals?








swimming for 2 days
or more, convulsions
Fish are held in test solu-










swimming for 2 days
or more, convulsions
Euthanasia by anaesthetic
overdose or blow to the
head:
Selected fish at sampling
time are caught by net,
rinsed, blotted dry and
instantly killed by strike
to the head followed by
cervical incision;
Remaining fish are
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behaviour or damaged ﬁn/tail) are present in one indi-
vidual or very small number of ﬁsh, any follow-up or
re-identiﬁcation of an individual ﬁsh is not or hardly
possible. Whenever it is possible to identify an individ-
ual aﬀected ﬁsh with subsequent observations, this may
be helpful in monitoring the clinical condition, appro-
priate for possible implementation of humane end-
points. If not, counting of the number of ﬁsh with the
typical clinical signs should be used to assess the con-
dition of the group of ﬁsh per tank.
Results and assessment of actual severity. During
the 84 days, 124 ﬁsh did not show any clinical
signs and were considered to have experienced
MILD severity. In test concentration 2, discolour-
ation was observed in one ﬁsh on three consecutive
days, followed by complete recovery. This was likely
to be the same ﬁsh on each day. Severity was con-
sidered MILD. In the control group, test concentra-
tion 1 and 2, one ﬁsh was found dead without prior
clinical signs. Severity was considered MILD. In both
the control group and test concentration 1, one ﬁsh
was circle swimming. After consultation of the desig-
nated veterinarian, these ﬁsh were kept in study and
closely monitored. Clinical signs disappeared in the
ﬁsh after two days. Severity in both ﬁsh was con-
sidered MODERATE. Finally, in test concentration
1, one ﬁsh was observed without a tail and humanely
euthanised. Severity: SEVERE.
Assessment: MILD for 127 ﬁsh, MODERATE for 2
and SEVERE for 1 ﬁsh.
Actions: As clinical signs exceeded prospective sever-
ity classiﬁcation, and after veterinary consultation,




A clinical score sheet can be used for daily observations
on mortality and adverse eﬀects. A clinical score sheet
may include several signs regarding swimming behav-
iour, pigmentation, appearance, reactive behaviour or
convulsions. Their presence or absence is documented
daily or more frequently is necessary. Any abnormal
and unexpected behaviour should be reported to the
researcher and/or designated veterinarian or suitably
qualiﬁed ﬁsh expert. If severe adverse eﬀects are
observed, it should be decided to monitor more fre-
quently and/or to implement humane end-points.
Considering the absence of identiﬁcation and group
density, follow-up on any observations on individual
animals may be impaired or non-realistic.
Example of a clinical score sheet is given below.
Severity assessment is performed by a combination
of these observations (together with a procedure for
evaluation). In case of combinations of observations
as described in the table, the highest score present is
used for assessment. If an observation is present for
more than one day in a row, the scores may be adjusted
(þ1, þ2 or þ3) in consultation with the researcher,
animal technologists and/or designated veterinarian or
ﬁsh expert. Close monitoring is helpful in the assess-
ment of actual severity on MILD, MODERATE or
SEVERE, especially in cases of sudden death with or
without previous clinical signs or in helping taking
Day of observation
Target concentration
Control Test concentration 1 Test concentration 2
0 no abnormalities no abnormalities no abnormalities
1 1 fish is dead no abnormalities no abnormalities
etc.
7 no abnormalities no abnormalities 1 fish is dead
etc.
14 no abnormalities 1 fish is circle swimming 1 fish is discoloured
etc.
16 no abnormalities 1 fish is dead 1 fish is discoloured
etc.
37 1 fish is circle swimming no abnormalities no abnormalities
etc.
72 no abnormalities 1 fish without tail (euthanised) no abnormalities
etc.
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informative decisions on timely implementation of
humane end-points.
Suggested severity assessment and actions based on
clinical observations:
References
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Description Scorea Action Severity assessmentb
Normal swimming, behaviour, appearance 1 NA MILD
Swimming behaviour
Bottom swimming 1 Check similarity controls MILD
Surface swimming 1 Check similarity controls MILD
Surface air gasping 2 NA MILD
Vertical swimming 3 Cumulative discomfort MODERATE
Swimming in side or supine position 3 NA MODERATE
Circle swimming (normal to supine position) 3 NA MODERATE
Pigmentation
Darker colouring 2 NA MILD
Appearance
Tail contraction 3 NA MODERATE
Haemorrhages/suggillation 4–5 (Consider) HEPc SEVERE
Visible damage to skin and/or fins 4–5 (Consider) HEP SEVERE
Reactive behaviour
Slow compared with control 2 NA MILD
Immobile 2 NA MILD
Hyperactive swimming after ticking against vessel 2 NA MILD
Hyperactive swimming 3 NA MODERATE
Other
Sudden death without previous signs 2 NA MILD
Sudden death with previous signs 2–5 NA MILD, MODERATE or SEVERE
Irreversible discomfort like convulsions 4–5 (Consider) HEP SEVERE
aIf an observation is also present on the second or third day in a row, the score is added þ1, 4 days in a row þ2 and 5 days in a row þ3.
This may facilitate severity assessment and implementation of HEP.
bIf a combination of observations is present, the severity assessment will be adjusted to the highest severity score of the observations
present.
cHEP¼ humane end-points.
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Assessment of acute oral toxicity with a
test substance in rats
General context
The Organisation for Economic Co-operation and
Development (OECD) test guidelines are a collection
of methods used to assess the hazards of chemicals and
of chemical preparations such as pesticides. These
methods cover tests for physical and chemical proper-
ties, eﬀects on human health and wildlife, and accumu-
lation and degradation in the environment. The OECD
test guidelines are recognised worldwide as the stand-
ard reference tool for chemical testing and are period-
ically reviewed in the light of scientiﬁc progress or
changing assessment practices. Acute oral toxicity
data are used to satisfy hazard classiﬁcation and label-
ling requirements, for risk assessment for human health
and the environment, and when estimating the toxicity
of mixtures. The objective of an acute oral toxicity
study is to assess the (near-)lethal toxicity of the test
substance following a single dose. The oral route is
selected as this may be a possible route of human
exposure.
The conventional acute oral toxicity test (formerly
OECD Test Guideline 401, the classic ‘LD50’ test),
1
requiring more than 20 animals is the most heavily
criticised test in terms of animal welfare and this con-
cern was the driving force behind its deletion and the
development of three alternative tests for acute oral
toxicity (OECD test guidelines 420, 423 and 425),2–4
respectively, the ﬁxed dose method (420), the acute
toxic class method (423), and the up-and-down proced-
ure (425). All guideline tests involve giving the test sub-
stance in graduated doses to groups of animals, which
are observed with respect to eﬀects and deaths (or
humane end-points). The result is given as a calculated
LD50 (the dose that kills 50% of the animals) or range
estimates of LD50. The ﬁxed dose method does not
require the death of animals as an end-point and uses
on average 5–7 animals with 1 death. The acute toxic
class and up-and-down procedure use on average 6–9
animals, with 0–3 deaths.5
Illustrative procedure
Study design. The acute toxic class method is a step-
wise procedure with the use of three animals of the
most susceptible sex (if unknown, female) per step.
All available information on the test substance (e.g.
identity and chemical structure, physico-chemical prop-
erties, other in vivo or in vitro toxicity tests, toxico-
logical data on the structurally related substances,
anticipated use(s) of the substance) should be con-
sidered prior to conducting the study.
The test substance should be formulated using a suit-
able vehicle and concentrations should be adjusted to
allow for constant dosage volumes. Animals should be
fasted prior to dosing to avoid interference with the test
substance by food present in the stomach; the guideline
requires ‘overnight’ fasting. Dosing volumes are chosen
according to good practice and vehicles according to
internal/external recipients databases.
The dose level to be used as the starting dose is
selected from one of four ﬁxed levels (5, 50, 300 and
2000mg/kg). There is an option to use an additional
dose level of 5000mg/kg, but only when justiﬁed by a
speciﬁc regulatory need. The starting dose level should
be that which is most likely to produce mortality in
some of the dosed animals. When available information
suggests that mortality is unlikely at the highest starting
dose level (2000mg/kg body weight), then a so-called
‘limit test’ should be conducted (6 rats, 3 rats per step).
When there is no information on a substance to be
tested, for animal welfare reasons it is recommended
to use the starting dose of 300mg/kg body weight.
Depending on the mortality and/or the moribund
status of the animals, further groups of animals are
dosed with higher or lower ﬁxed doses, depending on
the presence of mortality, until the study objective is
achieved; that is, the classiﬁcation of the test substance
based on the identiﬁcation of the dose(s) causing mor-
tality, except when there are no eﬀects at the highest
ﬁxed dose.
The time interval between treatment groups will be
based on onset, duration and severity of the toxic signs.
Treatment of next group will be delayed until no fur-
ther mortality is expected in previously dosed group(s).
On average 2–4 steps may be necessary to enable a
judgement with respect to classifying the test substance
to one of a series of toxicity classes deﬁned by ﬁxed
LD50 cut-oﬀ values.
In total, six rats will be used in this study. According to
the stepwise procedure, in step one, three rats will be
dosed by oral gavage at 300mg/kg as a starting dose.
Animals will receive a single oral dosing and then be
observed for 14 days. Observations include clinical
signs, body weight measurements and macroscopic
abnormalities during necropsy at the end of the observa-
tion period, or earlier if found dead or humanely killed.
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Consideration of specific refinements and humane
end-points.
What does this study
involve doing to
the animals?




make it worse? How will suffering be reduced to a minimum
Adverse effects
Methodology and interven-
tions to minimise severity End-points
Food deprivation over-
night prior to dosing
and until 3–4 h after
dosing of test sub-
stance. Water will be
available.
No pain, suffering or lasting
harm as food is deprived
once per rat, and BW is not
considered to get lower
than 80% of the mean of
the same sex/strain/age.
As fasting is performed
during the active phase and
may take up to 24 h, the
food deprivation is con-
sidered Mild as it may
cause some distress based
on behaviour and
physiology.
Fasting not longer than
physiologically advisable
(rat 6 h) and scientific
necessary to empty GI tract
or improve GI absorption of
substance is preferred over
overnight fasting according
to guideline but would need
prior acceptance by com-
petent authorities. Next
(2nd) group will be given
food immediately and not
be fasted/started, if (pro-
longed/suspected) mortal-
ity in earlier (1st) group is
present.
NA




ing gavage is considered
Mild. Good dosing tech-
niques/skills essential but
gavage accident may occur
rarely.
Well-trained personnel.
Gavage tube chosen to
provide minimum discom-
fort (appropriate size, flex-
ible plastic if allowed by




volumes based on weight/
species: e.g. maximum
dose volume of 10 ml/kg
BW. Maximum of three
single dosing actions within
24 h if higher volumes












toxic effect of sub-
stance after dosing
and during a 14-day
observation period
with group housing
Depending on the test sub-
stance. Local or systemic
Mild, Moderate or Severe
clinical signs or mortality
during the standard obser-
vation period of 14 days
after dosing may be
present.
Monitoring of mortality/via-
bility (at least 2/day).
Monitoring of clinical signs
(at least 3/dosing day and
once daily thereafter) and
body weights (at least
weekly). Interval between
subsequent groups at least
24 h. Next (2nd) group at the
next dose level will not be
fasted/started, if (pro-
longed/suspected) mortal-
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Initial prospective assessment. SEVERE: Substance
toxicity may result in up to SEVERE severity, as start-
ing dose levels are most likely to cause mortality in one
or more animals. Frequent observations after dosing on
day 1 (directly after dosing, 2 and 4 h later) and morn-
ing and evening checks are necessary to apply eﬀective
early end-points minimising severity.
In general, a severity classiﬁcation of SEVERE is
therefore appropriate.
Could the severity classiﬁcation be MODERATE?
Yes, if test substance information suggests mortality
to be unlikely at the highest starting dose level
(2000mg/kg BW) and mortality or any relevant
(delayed) clinical signs or mortality remain absent in
6 rats (3 animals per step), the severity may be con-
sidered MODERATE or even MILD.
Clinical observation. According to the guideline
(OECD TG 423), observations should be made in indi-
vidual rats after dosing at least once during the ﬁrst
30min, then periodically during the ﬁrst 24 h, with spe-
cial attention given the ﬁrst 4 h, and daily thereafter for
14 days.3 Duration of observation should be deter-
mined by toxic reactions, time of onset and length of
recovery period and may be extended when considered
necessary. Body weights are measured before dosing
and at least weekly thereafter. Body weight changes
should be recorded and used for welfare assessment
and/or early humane end-points. Any relevant macro-
scopic abnormalities during necropsy may be useful to
conﬁrm the correctness of chosen humane end-points.
Additional observations may be necessary if signs of
toxicity continue. Observations should include changes
in skin and fur, eyes and mucous membranes, and also
respiratory, circulatory, autonomic and central nervous
systems, and somatomotor activity and behaviour pat-
tern. Attention should be directed to observations of
tremors, convulsions, salivation, diarrhoea, lethargy,
sleep and coma. The principles and criteria summarised
in the OECD Humane Endpoints Guidance Document
should be taken into consideration.6 Animals found in
a moribund condition and animals showing severe pain
or enduring signs of severe distress should be humanely
killed.
A clinical score sheet or program (FELASA
Working Group Report, 2015) is useful for monitoring
animal welfare, identifying humane end-points as well
as reporting according to the OCDE guidelines.6,7 An
example of a clinical scoring system which is used to
help monitor the clinical condition of the animals
throughout the procedure is included at the end of
this example.
Results and assessment of actual severity. All trea-
ted rats in step 1 at starting dose of 300mg/kg showed
clinical signs. Clinical signs comprised lethargy,
hunched posture, uncoordinated movements, piloerec-
tion, ptosis, rales and/or salivation on Days 1 and 2
where one rat showed hunched posture also on days 6
and 7. No rats were found dead or needed to be killed
humanely, thus a second step was necessary according
to the guidelines. In step 2, with 3 rats dosed at
2000mg/kg, one female rat was found dead on Day 2,
showing slight body weight loss and clinical signs like
lethargy, hunched posture, piloerection, ptosis and sali-
vation between Days 1 and 2. No macroscopic
Continued
What does this study
involve doing to
the animals?




make it worse? How will suffering be reduced to a minimum
Adverse effects
Methodology and interven-
tions to minimise severity End-points
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abnormalities were found during necropsy of this
animal and other rats at the end of the study. No mor-
tality was observed in other rats. Body weight gain of
surviving rats was comparable to untreated animals of
same strain and age. For this purpose, historical data
on untreated or on same vehicle treated animals of
same strain and age may be used. Assessment:
SEVERE for the rat found dead, MODERATE for
the other rats.
Scoring system and examples of scoring
sheets
Severity assessment is performed by a combination of
clinical observations (changes in bodyweight, skin, fur,
eyes and mucous membranes, occurrence of secretions
and secretions and respiratory, circulatory, autonomic
and central nervous systems, somatomotor activity and
behaviour pattern.) based on a clinical scoring system
used in toxicology, and necropsy ﬁndings. Time of
onset, grade and duration of observed signs are rec-
orded. Signs are graded for severity and the maximum
grade is predeﬁned at 3 or 4. Grades are coded as slight
(grade 1), moderate (grade 2), severe (grade 3) and very
severe (grade 4). For certain signs, only its presence
(grade 1) or absence (grade 0) is scored.
Example of a clinical score sheet is given below. A
broad but not complete range of typical clinical signs,
are presented on the left (the range of scores is given per
clinical sign between brackets, e.g. 0–3 ranging from
absent to maximally present). This example refers to
an individual rat dosed at 300mg/kg BW in the ﬁrst
step with three rats.
Another example of the same study, now an individ-
ual rat dosed at 2000mg/kg BW in the second step with
three other rats. This rat dies on Day 2 after scheduled
observation. Only abnormalities in the clinical scoring
sheet over the observation period are shown.
Clinical signs D1-0 h D1-2 h D1-4 h D2 D3 D4 D5 D6
D7 etc.
up to 15
Bodyweight (g) 150 – – 145 150 152 155 158
Skin and fur: stains (0–1) 0 0 0 0 0 0 0 0 0
Skin and fur: pale (0–3) 0 0 0 0 0 0 0 0 0
Involuntary clonic movements (0–3) 0 0 0 0 0 0 0 0 0
Involuntary tonic movements (0–3) 0 0 0 0 0 0 0 0 0
Tremors (0–3) 0 0 0 0 0 0 0 0 0
Salivation (0–3) 0 1 0 0 0 0 0 0 0
Lacrimation (0–1) 0 1 0 0 0 0 0 0 0
Diarrhoea (0–1) 0 0 0 0 0 0 0 0 0
Vocalisations (0–1) 0 0 0 0 0 0 0 0 0
Stereotypy: excessive grooming (0–1) 0 0 0 0 0 0 0 0 0
Stereotypy: repetitive circling (0–1) 0 0 0 0 0 0 0 0 0
Bizarre behaviour: self-mutilation (0–1) 0 0 0 0 0 0 0 0 0
CNS: lethargy (0–3) 0 2 2 0 0 0 0 0 0
CNS: convulsions (0–3) 0 0 0 0 0 0 0 0 0
Posture: hunched posture (0–1) 0 1 1 0 0 0 0 1 1
Posture: rearing (0–1) 0 0 0 0 0 0 0 0 0
Posture: ventro-lateral recumbency (0–1) 0 0 0 0 0 0 0 0 0
Gait abnormalities: uncoordinated movements (0–3) 0 1 1 0 0 0 0 0 0
Piloerection (0–1) 0 1 1 0 0 0 0 0 0
Ptosis (palpebral closure) (0–3) 0 1 1 0 0 0 0 0 0
Respiratory abnormalities: laboured respiration (0–3) 0 0 0 0 0 0 0 0 0
Respiratory abnormalities: Rales (0–3) 0 1 1 0 0 0 0 0 0
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Pharmacokinetic study after single
administration of a test substance in
the dog
General context
The aim of the study is to study the pharmacokinetics
of a compound after single administration.
The diﬀerence in systemic exposure following oral (cap-
sule/tablet/gavage/diet), intravenous, dermal or sub-
cutaneous (bioequivalence) administration is assessed.
For substances intended to be ingested via the oral
route in humans, the oral route is compared to the
intravenous route, which is the reference route giving
100% bioavailability. The applicable testing guidelines
for the compound relate to any human exposure, pro-
spective use or legislation.1–10 The compound may con-
cern pharmaceuticals for human or veterinary use,
feeding ingredients or (agro-)chemicals.
Illustrative procedure
Study design. A common study design is to use the
same animals for two periods. In this example, three
dogs were used. In the ﬁrst period, plasma levels of
the compound following an intravenous dose are mea-
sured, then after an appropriate estimated wash-out, in
the second period, plasma levels of the compound fol-
lowing oral dosing of the same animals are measured.
Third or more periods with appropriate wash-outs may
be used to compare diﬀerent oral test substance formu-
lations (e.g. diﬀerent solutions, tablets, capsules). For
bioequivalence studies where a test compound is com-
pared to a known compound, a randomised block
design may be used to randomise the order of exposure
to diﬀerent routes and thus prevent any possible time
eﬀects from previous dosing. For bioavailability stu-
dies, where an unknown test compound is tested for
suﬃcient bioavailability in order to be used for further
studies, this may not be typically required. Urine and/
or faeces may be collected from animals kept in metab-
olism cages for the collection. After the study, it may
still be scientiﬁcally plausible to re-use the animal, and
it may be allocated to the ‘stock animals’. Fitness for
possible re-use will be based on age, lifetime and pro-
cedure-speciﬁc welfare assessment, restoration of gen-
eral health and well-being in accordance with veterinary
advice and classiﬁcation of further procedures. A total
of 4 periods, ﬁrst period of intravenous dosing followed
by three periods of diﬀerent capsule dosing, each with a
1 week wash-out period in between the dosing periods,
were used in the study. Observations comprised clinical
signs and body weight measurement before each dosing
period.
Clinical signs D1-0 h D1-2 h D1-4 h D2 D3 D4 D5 D6 D7 etc. up to 15
CNS: lethargy (0–3) 0 1 1 1 – – – – –
Posture: hunched posture (0–1) 1 1 1 1 – – – – –
Piloerection (0–1) 0 1 1 1 – – – – –
Ptosis (palpebral closure (0–3) 0 2 1 1 – – – – –
Salivation (0–3) 0 0 0 1 – – – – –
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Consideration of specific refinements and humane
end-points.
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make it




Food deprivation in oral
dosing study up to 20–
24 h before dosing
(‘overnight fasting’) to
improve GI absorption,




Or: diet may be offered for
same GI absorption
reasons in parts pre-or
post-dosing)
In general, not regarded as a
procedure causing dis-
comfort in adult dogs rou-
tinely fed once daily (if
normally fed twice daily, it
would be regarded as a
procedure). If exceeding
24 h based on post-dosing
fasting or in juveniles, it
may cause discomfort.
Depending on duration of
food deprivation and effect
of test substance like
vomiting or local GI effects:




due to GI effects.
Preferably no longer
than physiologically
advisable (dog 12 h)
and scientific neces-
sary to empty GI tract
to improve GI
absorption of sub-










not necessary but if
indicated, of limited
duration like 2 h pre-
and 2 h post-dosing,
exact amount of water
may be dosed by oral
gavage after dosing of
test substance)
No discomfort or dehydration
expected, transient MILD
discomfort if oral gavage

























Some study design may
involve testing of
metabolites next to test
Transient MILD discomfort
depending on dosing route,
restraining, possible
anaesthesia (with intratra-




Though non-toxic doses are
used, unexpected effects
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Continued
What does this study
involve doing to
the animals?
What will the animals
experience? How much
suffering might it cause?
What might make it








in the animal with con-
sideration of appropri-
ate wash-out periods.
MILD to MODERATE discom-
fort due to repeated dosing






sia. Mixing with pal-




(e.g. jugular vein) after
single dosing for toxico-
kinetics (oral dosing:
e.g. pre-dose, 8 in first
24 h, then 5 time points
up to day 5; IV dosing:
e.g. pre-dose, 10–12 in
first 24 h, then 2 time
points until day 3, or up
to 4–5 time points up to
day 4–5)
(Re)Introduction of needle
causing no or MILD dis-
comfort depending on pos-
sible habituation effect to












mally limiting in this
species/design (fre-
quent small volumes














urine sampling by col-
lection of spontaneous
urine in one or two 24 h
periods)
Social isolation. Metabolism
cage may prevent tactile
contact in a limited time
period but olfactory, visual
and auditory contact is still
present. Below threshold if
short period (metabolism
cage 24 h).
If longer than 24 h, it may be
Mild.
Promote visual, olfac-
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Initial prospective analysis of severity. Animal is only
expected to experience MILD discomfort based on lim-
ited food deprivation/water restriction, limited individ-
ual housing, single dosing, and repeated blood sampling.
Test substance eﬀects are expected to be absent or very
limited due to levels considered pharmacological.
A prospective severity classiﬁcation of MILD is there-
fore appropriate
Could the severity classiﬁcation be MODERATE?
Single dosing of test substance and frequent blood
sampling in the dog is considered to be MILD based on
species character/behaviour (social interaction with
humans), restraining method, and best practice dosing
& sampling technique/volumes used. MODERATE
severity seems unlikely prospectively as not toxic, but
pharmacologic, doses are to be used, but may be caused
by unexpected test substance (or vehicle) eﬀects or pos-
sible complications during dosing and sampling.
Clinical observations. Veterinary examinations are
performed before start of study (at arrival from the
supplier or at periodic intervals in the animal stock)
to ensure the good state of health and ﬁtness for (re-
)use of the animal for the procedure. Body weights are
measured before each dosing period. When considered
necessary, veterinary examinations may be performed
during the study. During the study period, animals are
monitored on mortality/viability at least twice daily
and for clinical signs during dosing and the follow-up
period at least once daily.12
An example of clinical score sheet based on an indi-
vidual observation (applicable score grade ranges
between brackets):
Severity assessment is performed by a combination
of general clinical observations (body weight, appear-
ance, behaviour, cage environment) based on a clinical
scoring system used in toxicology. Time of onset, grade
and duration of observed signs are recorded. Signs are
graded for severity and the maximum grade is prede-
ﬁned at 3 or 4. Grades are coded as slight (grade 1),
moderate (grade 2), severe (grade 3) and very severe
(grade 4). For certain signs, only its presence (grade
1) or absence (grade 0) are scored.
Results and assessment of actual severity. In the
ﬁrst period, no mortality occurred. In the ﬁrst period
of intravenous dosing, one animal (no. 3 in the exam-
ple) showed clinical signs like slight/moderate tremor,
slight lethargy, hunched posture, vomiting of food and
mucus, faeces containing mucus, and/or faeces with red
particles for a period of 2 h, followed by a quick and
complete recovery. Assessment: MILD.
The mild but nevertheless clear clinical signs of rela-
tively short duration after IV dosing could indicate
similar signs for a longer duration after oral dosing.
Period: 1 2 etc.
Date: D1 D2 D3 D4 D1 D2 D3 D4





Food intake (in g)
Salivation (0–3)
Vomiting (of food) (0–1)








Faeces containing mucus (0–1)
Faeces with red particles (0–1)
Hyperthermia
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Therefore, the prospective assessment for periods of
oral dosing was upgraded to MODERATE. Before
continuation of the study, the CA was notiﬁed on the
upgrade of the prospective assessment.
In the second (oral dosing) period, the animals
showed no clinical signs. Assessment: MILD. In the
third and fourth period (oral dosing with diﬀerent cap-
sules), one animal showed hyperthermia, vomiting of
food, hunched/abnormal postures and gait, ventrolat-
eral recumbency muscle switching, tremor and lethargy,
salivation, tachypnoea followed by recovery at the end
of the day. Assessment: MODERATE.
Examples of clinical score sheets
The clinical scores per animal over the dosing periods
are a selection of signs observed in this study example
and just a part of a complete list of clinical signs with
their scores available.
Example of clinical scores in animal 1:
Period: 1 2 3 4
Date: D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4
Body weight (kg) 9.9 – – – 9.9 – – – 9.9 – – – 10 – – –
Vomiting (of food) (0–1) 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
Tremor (0–3) 2 0 0 0 0 0 0 0 3 0 0 0 3 0 0 –
Faeces containing mucus (0–1) 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 –
Example of clinical scores in animal 3:
Period: 1 2 3 4
Date: D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4
Body weight (kg) 10.7 – – – 10.5 – – – 10.6 – – – 10.6 – – –
In heat (0–1) 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
Example of clinical scores in animal 3:
Period: 1 2 3 4
Date: D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4
Body weight (kg) 10.3 – – – 10.0 – – – 10.0 – – – 9.9 – – –
Lethargy (0–3) 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
Salivation (0–3) 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 –
Vomiting (of food) (0–1) 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
Vomiting of mucus (0–1) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 –
Tachypnoea (0–1) 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
Tremor (0–3) 2 0 0 0 0 0 0 0 3 0 0 0 3 0 0 –
Muscle twitching (0–1) 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
Hunched posture (0–1) 1 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
Abnormal posture (0–1) 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 –
Ventrolateral recumbency (0–1) 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
Abnormal gait (0–3) 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 –
Faeces containing mucus (0–1) 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 –
Faeces with red particles (0–1) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 –
Hyperthermia (0–1) 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 –
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Assessment of actual severity in the three
examples
Cumulatively over the four dosing periods, during
actual severity assessment, two animals were considered
as MILD; one animal was considered as MODERATE
over all four dosing periods.
Actions
As clinical signs are usually noted just after (IV) and/or
during the ﬁrst day after dosing (PO), closer monitoring
may be essential in case of unexpected moderate to
severe adverse eﬀects, supported if necessary by veter-
inary consultation, notiﬁcation to CA before continu-
ation and any intervention like humane killing in case
of humane end-points.13 If moderate to severe adverse
eﬀects are noted in the ﬁrst animal, a staggered start
(some time interval between ﬁrst and second or each
animal, with consideration of expected duration of pos-
sible clinical signs) and reconsideration of the dosage is
considered good practice. Also any possible diﬀerences
between sexes need to be considered before the study
or, if unknown, in the study design (e.g. starting with
one animal per sex, then following animals of each sex).
After the last dosing and observation period, in case
of mild up to moderate eﬀects, the dogs are released
from the study and monitored in stock until no further
abnormalities are observed. In case of any planned re-
use, it should be demonstrated that the general health
and well-being of the animal has been fully restored
until use for any next study will be considered. This
assessment should be in accordance with veterinary
advice and preferably supported by periodic clinical
and laboratory examinations. If necessary, based on
these ﬁndings and bioanalysis data (elimination half-
time determined) in the study, an appropriate wash-
out period between studies should be considered.
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